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DISSERTATION ABSTRACT
Molecular insights into the uropathogenesis of Enterococcus faecalis and Escherichia
coli in the context of urinary catheterization
by
Pascale Schaaba Guiton
Doctor of Philosophy in Biology and Biomedical Sciences
(Molecular Microbiology and Microbial Pathogenesis)
Washington University in St. Louis, 2012
Professor Scott J. Hultgren, Chairperson
Professor Michael G. Caparon, Co-Chairperson

Nosocomial urinary tract infections (UTIs) are a very common result of
catheterization with 3 to 7% risk of developing catheter-associated UTIs (CAUTIs) each
day catheterized. As multi-drug resistance increases in uropathogens, it is imperative to
better understand the effects of catheterization on the urinary tract and pathogenesis.
Further, microbial colonization and biofilm production on the surface of urinary catheters
are a common component of CAUTIs. Thus, this dissertation focuses on understanding
the contribution of known biofilm determinants to urovirulence of Enterococcus faecalis
(a common nosocomial uropathogen) and uropathogenic Escherichia coli (UPEC) (the
most common causative agent of UTI), and the effects of catheterization on bladder
physiology using in vitro and optimized in vivo models. In vitro studies reported here
demonstrated that E. faecalis produces DNA-dependent biofilms, which require both
SrtA and Atn for efficient attachment as well as extracellular DNA from autolytic
processes during the accumulative phase for maturation and architectural stability of the
ii

biofilm under both static and hydronamic conditions. Further, in vivo studies optimizing
and using a rodent model of foreign body-associated UTI to mimic conditions of
indwelling urinary catheters in humans underscored the importance of biofilm formation,
although in vivo required only a subset of the identified in vitro biofilm-promoting factors
such as sortases, for the establishment of persistent enterococcal UTIs despite the acute
inflammatory response ensuing from urinary implantation. This response was
characterized in these studies and shown to involve bladder wall edema, partial disruption
of the epithelial layer, vascular permeability, production of pro-inflammatory cytokines,
and recruitment of myeloid cells, particularly neutrophils. During infection of implanted
murine bladders, it was shown that type 1 pili mediate UPEC adherence and invasion,
similar to what was observed in non-catheterized bladders. Studies in this murine model
further demonstrated that microbial reservoirs established during previous UPEC
infection could serve as a nidus for urinary catheter colonization upon subsequent
implantation. Specific targeting of type 1 pili with small molecule inhibitors of the pilus
tip adhesin, FimH, in combination with trimethoprim/sulfamethoxazole prevented UPEC
CAUTI. This finding establishes a proof-of-principle for the development of novel
therapies to prevent and eventually treat UPEC CAUTI in the face of the rise of antibiotic
resistant uropathogens.
Overall, the optimization and use of the murine model of foreign body-associated
UTI represents a significant advance in the understanding of the pathophysiology of E.
faecalis and UPEC uropathogenesis in CAUTIs and is a valuable tool for the
identification of virulence factors, including enterococcal sortases and UPEC type 1 pili,
involved in these infections. Further research is required to uncover other biofilm and
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virulence determinants specifically required for UTIs as well as host factors that can
serve as potential antimicrobial targets and biomarkers for the prevention, diagnosis, and
treatment of enterococcal and UPEC CAUTIs.
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INTRODUCTION
Urinary tract infections
With more than 11 million cases diagnosed annually and half a million
hospitalizations1, urinary tract infections (UTIs) are among the most frequent infectious
diseases acquired in the community and healthcare settings2,3. The associated cost of
these infections is estimated at $3.5 billion every year in the United States1,4. UTIs are an
inflammatory bacterial infection of the urinary bladder and urethra (lower UTI or cystitis)
or in the ureters or kidneys (upper UTI or pyelonephritis) that can be associated with
symptoms including fever, abdominal and flank pain, and painful urination5.
UTIs are classified as uncomplicated or complicated based on patient’s medical
history and the use of instrumentation. Uncomplicated UTI occurs mostly in healthy
individuals with no abnormalities to the urinary tract. They typically affect young,
sexually active and non-pregnant women with a lifetime risk of 60.4%6. A subset of these
women will experience a recurrent episode within 6-12 months7-10. UTIs are also
prevalent among infants and children and are associated with vesicoureteral reflux
(VUR), severe renal dysfunction and scarring, and predisposition to recurrent
infections5,11. On the other hand, complicated UTI is defined by the onset of local and
systemic symptoms similar to those associated with pyelonephritis, including flank and
back pain, fever, and malaise, occurring in both men and women of all ages that have
functional or anatomic abnormalities in their urinary tract, the immunocompromised,
those suffering from other medical conditions such as nephrolithiasis and fibrosis, or
individuals undergoing long term urinary catheterization5.
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Catheter-associated urinary tract infections
Catheter-associated urinary tract infections (CAUTIs) are the most common
complications resulting from the use of indwelling urinary catheters12,13 and account for
40% of all nosocomial infections14 with more than one million cases diagnosed annually
in hospitals and nursing homes in the United States and an estimated cost of $600 million
in medical expenditures every year12,15,16. CAUTIs are defined as symptomatic UTIs with
urine culture of one or more bacterial species greater than 1,000 colony forming unit
(CFU)/ml with neutrophils present or pyuria, otherwise 105CFU/ml17. The incidence of
bacteriuria following urinary catheterization is extremely common and occurs at a rate of
3% to 10% daily18,19 with a 3 to 7% risk each day of developing CAUTIs20. This high
incidence of bacteriuria in catheterized patients complicates the diagnosis of CAUTIs
because both asymptomatic and symptomatic patients will have bacteria present in their
urine21. Yet both bacteriuria and pyuria, strong identifiers of uncomplicated UTIs, are not
good correlates of CAUTI22. It is thus imperative to identify specific biomarkers of
CAUTIs for better diagnosis and treatment.
Empirical antimicrobial therapy using oral antibiotics, including trimethoprim,
cephalosporins, and fluoroquinolones, are often sufficient to alleviate symptoms of
UTIs23. However, prevention and treatment are impeded by the ever-increasing rise in
antibiotics resistance among uropathogenic strains. If left untreated, CAUTIs can lead to
severe complications such as acute pyelonephritis, bacteremia, urosepsis, and in some
cases, death18,24. The high incidence of CAUTIs coupled with their medical and economic
challenges underscore the need for better understanding of CAUTI pathogenesis that can
help in the development of more effective therapies.
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Pathophysiology of CAUTIs
The pathophysiology of CAUTIs involves severe alterations of bladder
homeostasis following urinary catheterization. Catheterization induces histological and
immunological changes in the bladder leading to severe bladder wall edema, hematuria,
urothelial hyperplasia, and immune cell infiltration even in the absence of bacterial
colonization25-30. The insertion and presence of a urinary catheter also interferes with
micturition causing urine pooling in the bladder, damages the urothelium preventing
secretion

of

inhibitory

factors

such

as

Tamm

Horsefall

proteins

and

mucopolysaccharides, and alters urine characteristics such as osmolarity; all of which are
innate defense mechanisms that prevent microbial growth in healthy bladders31-34. Thus,
the disruption of the normal mechanical and antimicrobial defenses of the bladder
following urinary catheterization33,34 renders the bladder environment vulnerable to
microbial adhesion, multiplication, and dissemination within the urinary tract35,36.
Indwelling urinary catheters also provide an additional surface for microbial
attachment and biofilm formation37. Biofilm on the surface of urinary catheters is a major
component of the pathophysiology of CAUTIs and other chronic device-associated
persistent infections such as cystic fibrosis and endocarditis5,38-40. These are bacterial
communities encased within an extracellular matrix composed of carbohydrates, proteins,
nucleic acids, and lipids41,42. The development of a biofilm is a complex multi-stage
process depicted in Fig. 143. It is initiated with a primary adhesion of the bacteria to a
substratum, which is followed by the formation of microcolonies and production of an
exopolysaccharide matrix, and finally culminates with the formation of a three
dimensional multicellular mature structure44.
3

Figure 1: Proposed model of biofilm formation of the surface of urinary catheters
Following the insertion of the urinary catheter into the bladder, it is coated by host factors present
in the urine. Bacteria introduced from the periurethral or extracellular milieu attach to the urinary
catheters, multiply to produce microcolonies with secretion of an extracellular matrix. The
microcolonies mature to form mature 3-dimensional structure, called biofilms. Eventually cells
can detach or are shed for the biofilm to start the process again or disseminate to other tissues.
Adapted from Reference43.

Once formed, biofilms constitute an ideal environment for exchange of genetic
material, such as genes encoding virulence factors and antibiotic resistance determinants
among bacteria within the community45,46. Additionally, biofilm matrices allow for the
flow of water and nutrients as well as ions and various small molecules to bacteria within
the community42,47 and provide a protective shield against antibiotics, antimicrobial
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substances, and host immune defenses such as phagocytosis48-54, leading to chronic or
recurrent infections that are difficult to treat.
Etiologic agents of UTIs
Uropathogenic Escherichia coli (UPEC) is the major etiological agent of all UTIs,
responsible for 80% of community-acquired UTIs and over 50% of nosocomial UTIs55.
Emerging uropathogenic strains including Pseudomonas, Klebsiella, Staphylococci, and
Enterococci are responsible for the remainder of UTIs, especially in nosocomial settings.
Enterococcus faecalis and Enterococcus faecium, responsible for 15 to 30% of CAUTIs,
are now the third leading cause of hospital-acquired UTIs18,56. UPEC and Enterococci are
major etiological agents of CAUTIs56 and are often isolated from mono and
polymicrobial communities on the surface of urinary catheters with other Gram-negative
and Gram-positive bacteria, including Pseudomonas aeruginosa, Proteus mirabilis, and
Staphylococcus species57,58. Given their prevalence, medical and economic burden,
further research is warranted to understand the mechanisms underlying UPEC and
enterococcal CAUTIs.
UPEC uropathogenesis
E. coli, a rod-shaped facultatively anaerobic Gram-negative bacterium, is a
member of the microflora of the gastrointestinal tract in humans. However, subsets of
these Enterobacteriacae have acquired virulence factors that enable the establishment of
various infections in the human host, including sepsis, meningitis, diarrhea, and UTI.
UPEC, the major cause of all UTIs, belong to the extraintestinal pathogenic E. coli
(ExPEC) subsets. UPEC are equipped with an arsenal of virulence factors that ensure
colonization of the urinary tract while evading the host immune defenses43,59. Of
5

particular interest are the surface adhesins and extracellular fibers, including curli, pili,
Dr adhesins, antigen 43, cellulose and flagella, that mediate adherence to urinary
catheters and epithelial cells in the urinary tract, promote biofilm formation and
contribute to the establishment of cystitis and pyelonephritis60,61. The adhesive type 1 pili,
encoded by fim and which display phase variable expression, are the most prevalent
virulence factor present in 80 to 100% of UPEC strains 43.
Like many other bacterial fimbriae,
type 1 pili shown in Fig.2 are
assembled and translocated to the cell
surface via the conserved chaperone
usher pathway. Type 1 pili consist of

Figure 2: Type 1 pili are critical for UPEC

the major subunit FimA that makes up

adherence to uroepithelial cells.

the pilus shaft, the tip fibrillum
Electron micrographs of type 1 pili mediating UPEC

composed

of

FimF

subunits,

and

the

and

FimG

binding to uroepithelial cell surfaces prior to
bacterial engulfment. Adapted from Reference62.

tip

adhesin

FimH63,64. Type 1 pili mediate UPEC
binding to uroepithelial cells65 and are critical for UPEC infections66. The uropathogenic
cascade of UPEC illustrated in Fig.367 has been extensively characterized using a murine
model of cystitis60,68,69. It is a multistep process that is initiated with FimH of type 1 pili
binding to glycoprotrein uroplakins and mannosylated residues on the surface of the
superficial umbrella cells lining the bladder epithelium70. Following UPEC adhesion to
urothelial cells, bacteria are internalized via zipper-like mechanisms involving local actin
rearrangement and rhoGTPases71,72. UPEC replicate rapidly within bladder epithelial
6

cells to produce type 1 pili-dependent intracellular bacterial communities (IBCs) that
possess biofilm-like properties73,74, including positive periodic acid-Schiff (PAS)
staining, differential gene expression, and morphological differentiation67,73,75. Upon IBC
maturation, rod-shaped and filamentous bacteria then flux out from the infected cells and
reinvade neighboring cells and start the process de novo73.

Figure 3: Schematic of the acute phase of UPEC uropathogenic cascade.
Following attachment and invasion of the superficial umbrella cells of the bladder, UPEC
replicate, undergo morphological changes and develop intracellular bacterial community
(IBCs) composed of coccoid and filamentous bacteria. Upon maturation, bacteria emerge
from the infected cells and can reinvade neighboring cells to start the cycle over or establish
quiescent intracellular reservoirs (QIRs) that can persist for a long period of time in the
bladder. Reproduced with permission from Reference67.

This acute phase of UPEC infection can eventually lead to the development of chronic
cystitis, pyelonephritis, and the formation of quiescent intracellular reservoirs (QIRs)
with absence of bacteriuria, which is postulated to be a source of persistent and recurrent
7

infections76,77. IBCs are also present in exfoliated uroethelial cells in urine from UTI
patients, indicating that this pathway occurs during human infections78. The occurrence
of this uropathogenic cascade following urinary catheterization as well as the role of type
1 pili and UPEC biofilm in CAUTI have yet to be characterized.
The detailed understanding of the molecular mechanisms underlying UPEC
biofilm formation and uropathogenesis has led to the development of small molecule
inhibitors targeting the assembly (pilicides and curlicides) and function (mannosides) of
UPEC adhesive structures79-82. Pilicides and curlicides are dihydro thiazolo ring-fused 2pyridone derivatives that block protein-protein interactions required for the assembly of
type 1 pili and of curli amyloid fibers80,83. In contrast, mannosides are specific type 1
pilus adhesion, FimH, antagonists rationally designed to interfere with FimH interaction
with mannosylated residues present on the surface of the uroepithelium80,81,84-86. These
small molecules display anti-biofilm activity against UPEC in vitro and significantly
attenuate virulence in the urinary tract80,83. Furthermore, mannosides can be used in
combination with existing antibiotic therapy to prevent and treat UTI in mice87.
Virulence-based therapeutic approaches may thus provide potential alternatives or
supplement existing ones in the fight against UTIs, especially CAUTIs.
Enterococcal biofilm formation and urovirulence
Unlike UPEC, very little is known about enterococcal uropathogenesis.
Enterococci are Gram-positive facultative anaerobic lactic acid-producing bacteria found
as diplococci or in chains in the microbiota of the gastrointestinal tract of humans and
animals88. They are non-spore forming bacteria that can withstand and grow in harsh
environmental and physiological conditions, including high salt concentrations (6.5%
8

sodium chloride and 40% (w/v) bile salts), a wide range of pH (4.5-10.0) and
temperatures (10-45ºC). These physiological properties and the production of
antimicrobial peptides that are bactericidal to closely related species have led to the use
of Enterococcus species for biotechnology and as probiotic agents in the food industry88.
However, Enterococci, especially E. faecalis and E. faecium, are also important
opportunistic pathogens causing 12% of nosocomial infections89, including UTIs,
endocarditis and bacteremia which has a high mortality rate up to 61%90.
The ability of E. faecalis isolates to adhere to and develop biofilms on the surface
of medical devices such as intravascular and urinary catheters shown in Fig. 291-94,
coupled with the increasing resistance to virtually all antibiotics, including
aminoglycosides and glycopeptides such as vancomycin90,95-97, especially in biofilms98,99.
Vancomycin-resistant enterococci (VRE) have been associated, since their identification
in Europe in the 1980s100,101, with several
nosocomial infection outbreaks. In the
United States, the Center of Disease
Control and Prevention National Healthcare
Safety Network reports that from January
2006 to October 2007, 4% of healthcareassociated

infections

result

Figure 4: Scanning electron micrograph

from

of E. faecalis strain OG1RF.

vancomycin-resistant E. faecium56. This
intrinsic and extrinsic resistance to antibiotics and the transfer of resistance genes to other
species such Staphylococci102 pose important clinical challenge in the fight against
enterococcal infections. Several genetic factors and cellular processes, such as cell
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surface adhesins, proteases, quorum sensing, autolytic processes and extracellular DNA
(eDNA), are implicated in biofilm development91,103,104.
Although the mechanisms of biofilm formation in E. faecalis require further
research, enterococcal biofilm determinants, including the enterococcal surface protein
Esp105, the pilus-associated sortase C (SrtC)106, and the endocarditis and biofilmassociated pilus (Ebp)107, contribute to enterococcal urovirulence. On the other hand,
other well-characterized adhesins and in vitro biofilm determinants often associated with
enterococcal UTI isolates like aggregation substance (AS) and the housekeeping sortase
A (SrtA)108,109 were reported to be dispensable for virulence in the urinary tract108,109.
Since these conclusions were drawn from studies in murine models where persistent
enterococcal infections cannot be established, it is imperative to re-examine the existing
paradigm in an animal model that better mimics the transition of E. faecalis from a
commensal to a virulent pathogen in the urinary tract.
Prospectus
The introduction of multidrug resistant Gram-positive and negative bacteria in the
sterile environment of the bladder following urinary catheterization leads to the
development of CAUTIs, major nosocomial infections recalcitrant to antibiotic treatment.
Biofilm formation on the surface of indwelling urinary catheters is critical during
CAUTI; however, limited research exists addressing the role of biofilm promoting factors
in the establishment of CAUTIs, especially caused by UPEC and Enterococcus species.
Studies addressing the hypothesis that known biofilm determinants of E. faecalis and
UPEC are also involved in urovirulence following urinary catheterization and can serve
as novel targets for virulence-based therapy in the prevention and treatment of these
10

infections are presented in the following chapters. The study described in this thesis
provides molecular details of the temporal and spatial development of E. faecalis
biofilms. Subsequent chapters describe the optimization and use of a murine model of
CAUTI to assess the role of known biofilm factors to urovirulence of E. faecalis and the
consequences of urinary catheterization on the uropathogenic cascade of UPEC.

11

CHAPTER ONE
ENTEROCOCCAL AUTOLYTIC PROCESSES AND SORTASES MEDIATE
EXTRACELLULAR DNA-DEPENDENT BIOFILM FORMATION
Modified from: Guiton, P.S., et al. (2009) Infect Immun.
ABSTRACT
Biofilm production is a major attribute of E. faecalis clinical isolates. Although
factors such as sortases, autolysis and extracellular DNA (eDNA) have been associated
with E. faecalis biofilm production, the mechanisms underlying their contributions to this
process requires further investigation. The present study defines important roles for the
major E. faecalis autolysin (Atn), eDNA, and sortase A (SrtA) during the developmental
stages of biofilm formation under static and hydrodynamic conditions. Deletion of srtA
affects the attachment stage and results in deficiency in biofilm production. Autolysindeficient mutants are delayed in biofilm development due to defects in primary adherence
and DNA release, which is particularly important during the accumulative phase for
maturation and architectural stability of biofilms. Confocal laser scanning and freeze-dry
electron microscopy of biofilms grown under hydrodynamic conditions revealed that E.
faecalis produces a DNaseI-sensitive fibrous network important for biofilm stability. This
DNA-dependent fibrous network is absent in atn-deficient mtutant biofilms. Overall, this
study establishes the stage-specific requirements of SrtA and Atn and demonstrates a role
for the major enterococcal autolysin in the pathway leading to DNA release during
biofilm development in this opportunistic organism.
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INTRODUCTION
Bacterial biofilms can withstand harsh environmental stress conditions, including
low nutrient availability, temperature fluctuations, antibiotic and antimicrobial
treatments, and host immune responses38,110,111. Medical biofilms are associated with the
establishment

of

chronic

and

persistent

infections,

including

enterococcal

CAUTIs40,112,113. The ability of E. faecalis to adhere to and develop biofilms

91

on

medical devices, such as intravascular and urinary catheters, is thought to contribute to its
pathogenesis.
Several putative virulence factors and cellular processes have been implicated in
the development of biofilms in E. faecalis91,92,114-121; however, very little is known about
their regul91ation and molecular contribution during this process. One of these factors, the
quorum-sensing two-component transduction signaling system encoded by the fsr locus,
an important virulence factor in the pathogenesis of E. faecalis, controls biofilm
formation via positive regulation of the extracellular zinc metalloprotease GelE
(gelatinase) and the serine protease SprE115,117-120. These proteases were recently shown
to contribute to enterococcal biofilm formation via regulation of cellular autolysis and
fratricidal DNA release103,104. In these studies, Thomas et al. also provided the first
evidence for a critical role of extracellular DNA (eDNA) in E. faecalis biofilms104. eDNA
is an important component of the extracellular matrix of bacterial biofilms, providing
structural stability to the biofilm and protection against antimicrobials122-128. However,
the temporal and spatial requirements of this macromolecule throughout the
establishment and growth of E. faecalis biofilms is not well characterized.
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Bacterial murein hydrolases, also referred to as autolysins, have been implicated
in biofilm production127,129. They are important contributors to cell wall growth and
regulation as well as several lytic processes130,131. Two autolysins of Staphylococcus
epidermidis, AtlE and Aae, are adhesins that contribute to bacterial attachment to
polymeric

surfaces

and

biofilm

formation

via

release

of

eDNA127,132,133. E.

faecalis produces several autolysins, which were recently identified and characterized134137

. The major E. faecalis autolysin, Atn (also known as AtlA), is a predominant

enterococcal antigen during human infections138. Atn is an N-acetylglucosaminidase134
important for daughter cell separation139. Disruption of atn in E. faecalis results in
increased

chaining,

defects

in

primary

attachment,

and

decreased

biofilm

production92,103,109,136,137,139. Furthermore, inactivation of this autolysin partially protects
E. faecalis against the lytic activities of the β-lactams penicillin (in vitro) and amoxicillin
(both in vitro and in vivo), but does not attenuate virulence in mouse and rabbit models of
peritonitis and endocarditis, respectively139-141. However, the contribution of Atn to DNA
release during biofilm formation remains to be established. Recently, Thomas et al.
provided evidence that inactivation of this autolysin results in a decrease in DNA release
similar to that of gelatinase-deficient mutants103. Furthermore, they showed that GelE and
SprE can differentially cleave Atn in vitro, and this processing may underlie the
mechanism of cell death and DNA release in E. faecalis during biofilm formation.
Due to their role in cell wall regulation, autolysins may affect the localization of
cell wall-anchored proteins, which can be important for adhesion during biofilm
development. In most Gram-positive bacteria, membrane-anchored transpeptidase
enzymes known as sortases are responsible for sorting and covalently anchoring proteins
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bearing an LPXTG motif to the cell wall142

143

. Thus far, only class A and class C

sortases have been implicated in enterococcal biofilm formation and virulence106,109.
Deletion of the gene encoding sortase C, srtC or bps (biofilm and pilus-associated
sortase), resulted in a significant reduction in biofilm production and attenuation of
virulence in a mouse model of UTI, unlike deletion of srtA, which had minor effects
under similar conditions106. However, given the ubiquitous nature of sortases and the
limited knowledge of the activity and substrates of the sole SrtA characterized in E.
faecalis, it is plausible that this enzyme may play an important role in E. faecalis
physiology and/or pathogenesis under different conditions. For instance, SrtA was shown
to anchor the plasmid-encoded protein Asc10, which is involved in the pheromoneinduced aggregation of E. faecalis144.
The present study uncovers the contributions of E. faecalis SrtA, Atn and eDNA
to the major developmental stages from bacterial attachment to the establishment of
mature biofilms under static and hydrodynamic conditions. The findings indicate that
both SrtA and Atn contribute to efficient primary adherence to the abiotic surfaces while
Atn and eDNA promote biofilm maturation and architectural stability during the
accumulative stage. These findings argue for a role of Atn in the temporal regulation of
DNA release. Under hydrodynamic shear forces, E. faecalis produces an Atn-dependent
DNaseI-sensitive extracellular fibrous network. Collectively, this study underscores the
importance of SrtA and Atn-mediated DNA release at different stages during the
establishment of E. faecalis biofilms. As a critical component of the extracellular matrix
of E. faecalis biofilms, eDNA may serve as a novel target for the dissolution of these
structures.
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RESULTS
E. faecalis biofilm development occurs in two major steps
In order to delineate the major stages of E. faecalis biofilm development, OG1RF
was monitored for 72h to assess biofilm formation on polyvinyl chloride (PVC)
coverslips in trypticase soy broth supplemented with 0.25% glucose (TSBG) at 37ºC
under static conditions. Biofilms were visualized and quantified by CLSM and crystal
violet-based quantification. CLSM images of 24h and 72h OG1RF biofilms stained with
the DNA dyes SYTO9 and PI show a slow accumulation of the biofilm during the first
24h, which was followed by a rapid buildup and increase in density and thickness (Fig.
5A). Crystal violet-based quantification confirmed this observation and displayed a
biphasic biofilm growth curve. This curve shows that the biomass accumulated at a
slower rate between 0 and 24h followed by a significantly faster growth during the
subsequent 48h with an approximately 6 fold increase in biomass from 24h to 72h (Fig.
5B).
eDNA is required for biofilm development
SYTO9 is a membrane permeable DNA dye whereas PI stains only eDNA and
DNA of membrane compromised cells. The CLSM images show the presence of yellow
patches throughout the biofilms, which are representative of SYTO9 and PI colocalization due to the presence of dead cells or eDNA in these structures (Fig. 5A and
5C). To determine whether eDNA contributes to biofilm development, OG1RF was
grown statically in presence of varying DNaseI concentrations, ranging from 0 to
50µg/ml. DNaseI treatment severely impaired the ability of OG1RF to develop into
mature biofilms at concentration as low as 0.5µg/ml (data not shown). OG1RF grown in
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presence of 5µg/ml DNaseI produced 92.3% less biomass at 72h (p=0.0121 by MannWhitney U test) than untreated controls (Fig. 5B), which was in accordance with the
reduction in volume observed determined by SYTO9 absorbance (Fig. 5D). The
detrimental effects of DNaseI on biofilm development are not due to bactericidal or
bacteriostatic activities as DNaseI did not inhibit OG1RF planktonic growth (data not
shown). CLSM analysis further showed that OG1RF was able to attach to the substratum
and formed microcolonies in presence of DNaseI; however, it failed to build the large
compact 3D structures observed at 72h in untreated controls (Fig. 5C). In addition,
approximately 10 to 15% of the cells present in the DNase I-treated samples stained with
PI compared to the 30 to 50% in the untreated samples (Fig. 5D). The lower level of PI
staining in biofilms treated with DNase I indicates a reduction in the number of dead cells
and/or eDNA. Together, these findings suggest that eDNA in OG1RF biofilms
contributes to the establishment of mature enterococcal biofilm structures.
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Figure 4: DNA is critical for E. faecalis biofilms under static conditions.
(A) CLSM images of OG1RF biofilms at 24h and 72h. Biofilms were stained with SYTO9
(green) and PI (red) and visualized with CLSM. 3D reconstructions of z stacks were generated
with the Volocity software. (B) Crystal violet-based quantification of OG1RF biofilm biomass.
Error bars = SEM of at least 3 independent experiments. *p<0.05, ***p<0.0005 by MannWhitney U test (C) CLSM images of 72h static OG1RF biofilms untreated or treated with 5
µg/ml of DNaseI continuously or for 3 h post formation. Scale, 1 unit on each side of the grid
=14.3µm. (D) Quantification of biomass volume (µm3) based on SYTO9 and PI absorbance using
Volocity software. Graphs represents data obtained from a representative experiment with 3-4
randomly chosen fields. Error bars=SD
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eDNA is required for maintenance of biofilm architectural integrity
To further characterize the function of eDNA in enterococcal biofilms, the effects of
DNaseI on mature biofilms were investigated. Mature 72h static biofilms were treated
with 5µg/ml of DNaseI for 1h, 2h, 3h, and 24h at 37°C followed by crystal violet staining
or CLSM analysis. DNaseI treatment significantly reduced biofilm biomass by ~30%
compared untreated controls 2h post treatment (p=0.0428) (Fig. 6A). Three hours
treatment with DNaseI further reduced the biofilm biomass by 60% (p=0.008) while
inactivated DNaseI (iDNase I) did not have any significant effects (p=0.7602; Fig. 6A).
DNaseI inactivation was achieved following incubation at 75 to 100ºC and confirmed by
its inability to degrade salmon sperm DNA (SSDNA) following 1h incubation at 37ºC
(Fig. 6B). The biomass was further reduced to 40% of its original thickness (p=0.0003)
24h post treatment whereas iDNase I had no effect (p=0.5079; Fig. 6C). The disruption of
mature biofilms following DNaseI treatment was also observed by CLSM (Fig. 5C and
6C). Disintegration of the biofilm structures occurred at 3h following treatment with
5µg/ml of DNaseI (Fig. 5C) compared to 1h with 50µg/ml DNaseI concentrations (Fig.
6C), suggesting that the effect of DNaseI on biofilms is dose and time dependent.
Overall, these findings indicate that eDNA is an important structural component of E.
faecalis biofilms and is necessary for maintaining their stability.
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Figure 5: DNA is required for maintaining biofilm stability.

(A) Relative biomasses of 72-h OG1RF biofilms treated for 1 h, 2 h, 3 h, or 24 h with 5 µg/ml
of DNase I or iDNase I at 37°C. Error bars = SEM from three different experiments. *p < 0.05
** p < 0.01; *** p < 0.0005 by Mann-Whitney U test. (B) 0.8% agarose DNA gel showing the
activities of DNaseI and heat inactivated DNaseI (iDNase I) at 75ºC and 100ºC for 20 min
were assayed in TSBG at 37°C for 1h on 100µg/ml of salmon sperm DNA. (C) 72h old

OG1RF biofilms stained with SYTO9 (green) and PI (red) were untreated or treated
with 50 µg/ml of DNaseI or iDNase I for 1h, 3h, or 24h. Scale, 1 unit on each side of
the grid =14.3µm.
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E. faecalis forms a DNaseI-sensitive fibrous network under hydrodynamic
conditions

Figure 6: E. faecalis produces a DNaseI-sensitive extracellular fibrous network under
hydrodynamic conditions induces the production.
The images are freeze-dry electron micrographs (Magnification, x20,000) (A and D) and
CLSM images (B, C, and E) of 48h OG1RF biofilms untreated (A, B, and C) or treated for 1h
with 5 µg/ml of DNaseI (D and E). The arrows in (B and C) indicate SYTO9-PI stained fibers.
Biofilm fibers (in white square) stain only with DNA dyes and not WGA. SYTO9 (green), PI
(red), and WGA (blue). Scale bars = (A and D) 500nm, (B and E) 20µm, and (C) 10µm.
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E. faecalis must withstand a variety of environmental conditions, such as urine
flow in the bladder, for efficient colonization of medical devices. To investigate the
effects of shear forces on E. faecalis biofilm development, OG1RF biofilms were
cultivated in TSBG on PVC coverslips placed on an orbital shaker at 37ºC for the
duration of the experiment. Freeze dry and CLSM micrographs of 48h dynamic biofilms
show bacteria within the biofilm clustered via long fibrous structures under these
conditions (Fig. 7A-C) that only stained with the DNA dyes and not with wheat germ
agglutinin (WGA) that stains carbohydrates on cell surfaces (Fig. 7C). These
extracellular fibers disappeared within 1h of DNaseI treatment (Fig. 8D-E), which
correlated with disintegration of the biofilm. Additionally, immunogold transmission
electron microscopy (TEM) analyses of OG1RF hydrodynamic biofilms labeled with
mouse anti-dsDNA monoclonal antibody revealed foci inside and at the surface of cells
as well as in the extracellular matrix surrounding the cells (Fig. 8A, top left panel), while
examination of biofilms after 1 h of treatment with DNase I showed a reduced presence
of eDNA (Fig. 8A, top right panel). Approximately 38% of the gold particles labeled the
extracellular matrix compared to ∼6% following DNase I treatment (Fig. 8B). Similar to
the results for static conditions, OG1RF grown in the presence of 5 µg/ml of DNase I for
48 h failed to produce biofilms under hydrodynamic conditions and only 2% of the gold
particles were found in the extracellular milieu under such conditions (data not shown).
Treatment with proteinase K did not prevent OG1RF biofilm formation and did not affect
the formation of the DNase I-sensitive extracellular fibers (data not shown). These results
indicate that in the presence of hydrodynamic forces E. faecalis produces DNAdependent biofilms with a distinct architecture from that of static biofilms. Additionally,
22

the data suggest that eDNA is a major component of the filamentous extracellular
network in biofilms formed under hydrodynamic conditions that appears to provide cellto-cell adhesion and stability in the biofilms.

Figure 7: Atn contributes to DNA release during biofilm formation.
(A) Negative staining and immunoelectron microscopy images of 48h OG1RF and OG1RF∆atn
biofilms with or without 1h of DNase I treatment and labeled with mouse anti-dsDNA
monoclonal antibody and secondary immunogold. The images are representative images of 10
random fields. Scale bars = 200 nm. Graph represents quantification of cell-associated or
extracellular gold particles (indicated by arrowheads in panel A) from 10 independent fields for
48h dynamic biofilms at a magnification of x30,000.

Deletion of atn results in delayed biofilm formation
Freeze-dry electron micrographs revealed that lysed cells are constituents of
enterococcal biofilms (Fig. 9A). This observation led to the hypothesis that Atn, the
major autolysin of E. faecalis, facilitates DNA release and the formation of the DNase I-

23

sensitive extracellular fibrous network. To test this hypothesis, in-frame deletion of the
autolysin gene (atn) was performed to generate an autolysin-deficient strain in OG1RF,
OG1RFΔatn. The ability of OG1RFΔatn to form biofilms in the presence or absence of
DNaseI was assessed. Deletion of atn did not affect OG1RF growth rate under normal
culturing conditions (data not shown). As expected, based on the role of autolysins in cell
lysis and cell division, OG1RFΔatn had a reduced rate of cellular lysis as determined by
a cellular autolysis assay under both static and hydrodynamic conditions (Fig. 9B) and
formed longer chains than the parent strain (Fig. 9C). Compared to wild type OG1RF,
OG1RFΔatn was delayed in its ability to form biofilms under hydrodynamic conditions
and produced approximately 40% less biomass by 48h as compared to that of the parental
strain (Fig. 10A). Continuous DNase I treatment resulted in a ∼40% reduction in the
OG1RFΔatn biomass accumulated by 48 h (p = 0.038) compared to an 87% reduction for
the wild type (p= 0.0004; Fig. 10A). Similar levels of inhibition are observed following
1h

of

DNase

I

treatment

of

48-h

OG1RFΔatn biofilms

(Fig.10B-C).

For

OG1RFΔatn biofilms, there was a 33% decrease in biomass (p > 0.05) following DNase I
treatment compared to a 78% reduction for the wild-type structures (p < 0.0001)
(Fig.10B). CLSM analysis of 48h dynamic OG1RFΔatn biofilms revealed the absence of
DNase I-sensitive extracellular fibers and very few PI-stained cells (Fig. 10C-D).
Additionally, reduced amounts of eDNA were detected in the extracellular matrix of the
mutant biofilms using cryoimmunoelectron microscopy with murine anti-dsDNA
monoclonal antibody labeling (Fig. 8). Under static conditions, deletion of atn caused a
similar reduction in biofilm biomass. The structure produced in the absence of atn was
significantly more resistant to DNaseI treatment compared to wild type biofilms (Fig.
24

10A-C) and the cells within the static biofilms were loosely packed (Fig. 10B).
Complementation studies could not be performed with OG1RFΔatn expressing atn from
a vector, perhaps due to the potential cytotoxic effects of Atn in the recipients, as
previously suggested137. Nonetheless, the above findings indicate that Atn and cellular
lysis play a role in DNA release during enterococcal biofilm formation. However, the
ability of OG1RFΔatn to form delayed and partially DNase I-sensitive biofilm suggest
the existence of Atn-independent mechanisms of DNA release.

Figure 8: Effects of atn deletion.
(A) Freeze-dry electron micrograph of a 48h dynamic OG1RF biofilm with extracellular fibrous
network protruding from lysed cells (red square). Magnification, x30,000. Scale bar = 500 nm.
(B) Cellular autolysis of exponential-phase OG1RF and OG1RF∆atn in trypsin/sodium phosphate
buffer. Error bars = SEM from at least 3 independent experiments (C) OG1RF and OG1RF∆atn
cells from 24h TSBG liquid cultures stained with SYTO9 and PI. Scale bar= 10 µm.
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Figure 9: Characteristics of OG1RF and OG1RF∆atn grown in static conditions. (A) Crystal
violet-based quantification of OG1RF (WT) and OG1RF∆atn (∆atn) biofilms with or without
DNaseI treatment at indicated times. (B) CLSM images of 72h WT and ∆atn biofilms untreated,
treated continuously or post formation with 5 µg/ml of DNaseI. The cross-section images reveal
the thickness of the biofilms. Scale bar = 28 µm. (C) Crystal violet –based quantification of 72h
WT and ∆atn biofilms treated with or without DNaseI for 3h *p<0.05, **p<0.005, ***p<0.0005
by Mann-Whitney U Test.
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Atn contributes to DNA-independent attachment of E. faecalis to plastic surfaces
To assess the role of eDNA in initial attachment of E. faecalis to plastic cover
slips, a primary attachment assay was performed in presence or absence of 5µg/ml of
DNaseI under static and hydrodynamic conditions. Very few cells were adhered to the
substratum after 2h in either condition (data not shown). By 4h and 6h, significantly
fewer OG1RFΔatn cells (40%) than wild-type strain cells were adhered to the surface
(p < 0.0001; Fig. 11A), suggesting that Atn is required for this process. In contrast
to atn deletion, DNaseI treatment did not affect the primary attachment at 4h for both
wild-type strain OG1RF and OG1RFΔatn. Similar levels of wild-type cells were attached
to the surfaces regardless of the presence of DNaseI at 4 h (p = 0.3527) (Fig. 11A),
indicating that eDNA is not critical for the initial attachment stage during biofilm
development. Six hours of continuous DNase I treatment prevented microcolony
formation (Fig. 11B), and this corresponded with a 33.3% reduction in the number of
adherent cells. Albeit not statistically significant (p = 0.4359), this reduction suggests that
DNaseI affects microcolony formation; microcolonies were readily visible at 6 h only in
untreated samples (Fig. 11B). Furthermore, there was a >500% increase in PI staining
from 4 h to 6 h compared to approximately 200% increase in the presence of DNase I
(Fig. 11C), arguing that cell death and eDNA contribute to microcolony formation.
Similar findings were obtained under hydrodynamic conditions (data not shown).
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Figure 10: Primary attachment requires srtA and atn, but not eDNA.
(A) Primary attachment of OG1RF (WT), OG1RFΔatn (Δatn), OG1RFΔsrtA (ΔsrtA), and
OG1RFΔsrtA/srtA (ΔsrtA/srtA) was determined by crystal violet staining following static
incubation on PVC coverslips for 4 to 6 h at 37°C in TSBG with or without 5 µg/ml of DNase I.
error bars =SEM for at least three independent experiments. *, p < 0.05**, p < 0.01; ***, p<
0.0001 by the Mann-Whitney U test. (B) Representative CLSM images of 4h and 6h OG1RF (wt)
adherent cells in the presence or absence of DNase I stained with SYTO9 (green) and PI (red).
The arrows indicate microcolonies in 6h samples. One unit on each side of each grid equals 14.3
µm. (C) Quantification of the change in fluorescence of SYTO9 and PI relative to the total
fluorescence from adhering cells from 4 h to 6 h post inoculation from 12 randomly chosen fields
from two independent experiments using the VOLOCITY software.
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Deletion of srtA results defect in primary adhesion
Given that autolysins are involved in cell wall growth and regulation, it is
conceivable that deletion of atn causes mislocalization of adhesion factors critical for
primary attachment and biofilm development. Sortases are ubiquitous enzymes with
critical role in adhesion and virulence of Gram-positive bacteria. Given their role in cell
wall protein sorting and anchoring, SrtA substrates on the cell surface may,
hypothetically, contribute to initial stages of biofilm development. To investigate the role
of SrtA in biofilm formation under static and hydrodynamic conditions, an in-frame
deletion of srtA was generated in OG1RF, OG1RFΔsrtA. Deletion of srtA had no effect
on cell viability and cell growth (data not shown). Similar to OG1RFΔatn, OG1RFΔsrtA
was also significantly deficient in primary attachment under static (p=0.0001; Fig. 11A)
and shaking conditions (data not shown). Forty percent fewer OG1RFΔsrtA cells than
parental strain cells adhered to the coverslips after 4h of incubation. The complemented
strain OG1RFΔsrtA/srtA exhibited wild-type levels of adherence by 6h, showing
significantly more adherence than OG1RFΔsrtA (p = 0.0022; Fig. 11A). It is not clear
why the complementation effect was delayed and thus not observed at 4h; however, this
may have been the result of plasmid loss in the complemented strain population, which
allowed only a small subset to efficiently adhere to the substratum, leading to the
observed delay. Furthermore, preliminary data from TEM analysis of OG1RF,
OG1RFΔatn, OG1RFΔsrtA, OG1RFΔsrtA/srtA grown statically in TSBG for 24h
indicated that OG1RFΔsrtA produced fewer pili compared to wild type and the other
strains (Fig. 12). Together, these findings suggest that SrtA and likely a SrtA substrate(s)
play a role in promoting efficient initiation of biofilm development in E. faecalis.
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Figure 11: Piliation in OG1RF and isogenic mutants
Bacteria were grown statically in TSBG for 24h and prepared for TEM. Pili were counted on 500
cells per strain. Arrows indicate pili. Graph represents the percentage of piliation relative to
number of cells counted. Magnification, Scale bar = Experiment was performed once.
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srtA deletion results in defects in biofilm production
OG1RFΔsrtA was significantly defective in biofilm formation under static
conditions; it produced ∼60% less biomass than the wild type at 24 h (p = 0.0142) and
even less (~40% reduction) biomass than the wild type at later time points (p = 0.0244;
Fig. 13A). This defect in biofilm was complemented in OG1RFΔsrtA/srtA under static
conditions (Fig. 13B-C). OG1RFΔsrtA and the complemented strain formed 3D biofilm
structures that were sensitive 5µg/ml of DNaseI similar to wild type (data not shown).
Additionally, the role of srtA in biofilm formation was assessed in presence of shear
forces. In contrast to static conditions, the srtA-deficient mutant was severely defective
under hydrodynamic shear forces (Fig. 13D). The impairment observed under these
conditions

was

even

more

pronounced

compared

to

static

conditions.

OG1RFΔsrtA/srtA exhibited a wild-type phenotype under these conditions (Fig. 13D),
forming mature biofilms containing SYTO9-PI-stained extracellular fibers. These
findings suggest that DNA release and extracellular fibrous network formation occur
independent of SrtA.
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Figure 12: SrtA promotes high levels of DNA-dependent biofilm development.
(A) Crystal violet staining based quantification of OG1RF WT and OG1RFΔsrtA biofilm
development and of (B) 72h OG1RF WT, OG1RFΔsrtA, and OG1RFΔsrtA/srtA static biofilms.
Error bars = SEM of 3 different experiments. *p<0.05, **p<0.01 by Mann-Whitney’s test. (C-D)
3D reconstruction of CLSM images of static 72h biofilms (C) and 48h dynamic biofilms (D) of
OG1RF, OG1RFΔsrtA and OG1RFΔsrtA/srtA stained with SYTO9 (green) and PI (red). Scale, 1
unit on each side of the grid =14.3µm. White arrows indicate SYTO9-PI stained fibers. Scale
bar=10µm.
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DISCUSSION
Despite the identification of a myriad of genetic factors and cellular processes
involved in E. faecalis biofilm formation91,92,103,104,106,109,114,115,145-150, the molecular
mechanisms underlying E. faecalis biofilm are yet to be defined. In this study, two major
steps are delineated during E. faecalis biofilm formation: an initial attachment stage
involving binding to an abiotic surface followed by an accumulative phase during which
intercellular interactions to generate mature multicellular 3D biofilm structures. This
report provides evidence of the temporal and spatial contribution of Atn-mediated
autolytic processes and of the housekeeping sortase (SrtA) during biofilm formation.
The extracellular matrix of bacterial biofilms provides a safe haven for microbes
within the community protecting them from various environmental stresses42,47. eDNA is
a crucial structural component of the extracellular matrices of both Gram-negative and
Gram-positive bacteria biofilms. This macromolecule mediates primary attachment, cellto-cell adhesion, mature 3D biofilm architecture, and antimicrobial activities122,125,128,151153

. Thomas et al. showed that the vancomycin-resistant strain E. faecalis (V583) is

unable to produce biofilms in presence of DNase I104. Similarly, E faecalis OG1RF strain,
used in this study, is defective in biofilm formation following DNase I treatment. This
enzyme can also disintegrate mature OG1RF biofilms, implying that eDNA is an
important component of the extracellular matrix of E. faecalis biofilms and that this
macromolecule is involved in cellular clustering during biomass accumulation. Although
eDNA has similar functions under static and hydrodynamic conditions, its spatial
contribution varies. Static biofilms are more compact with higher cell densities than
biofilms formed in the presence of shear forces. Under hydrodynamic conditions, E.
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faecalis produces a DNase I-sensitive fibrous network, reminiscent of a stable fibrous
eDNA network of the aquatic Gram-negative bacterium strain F8154,155. Likewise,
nontypeable Haemophilus influenza biofilms formed in vivo contain extracellular fibrous
DNA networks156 derived from neutrophil extracellular traps157. Notably, Kristich et al.
also reported the presence of a filamentous extracellular network in enterococcal biofilms
of both wild type and transposon-inactivated atn mutant strains grown statically on
nitrocellulose membranes109. However, the composition of this structure was not
characterized.
Previous reports have implicated Atn in primary attachment and biofilm
production92,109, but its contribution to this process, especially in DNA release, remains to
be established. Atn is an important mediator of cell length and cell lysis during E.
faecalis growth. Unlike autolysins described for other Gram-positive bacteria such as Aae
and AtlE in S. epidermidis127,133, Atn contributes to initial adhesion in a DNAindependent fashion. Inactivation of this autolysin leads to increased cellular
chaining139,158 that may reduce binding sites or increase cell surface charges causing
lower cell deposition rate, thus explaining the adherence defects observed in atn-deficient
strains. Repulsive interactions occurring between abiotic surfaces and bacteria as well as
between adherent cells and incoming cells caused by surface charges were previously
shown to influence the initial adhesion of bacteria to substrata159,160. Alternatively,
defects in autolytic processes may alter the cell wall structure and localization of surface
proteins required for attachment during biofilm formation, resulting in the deficient
attachment and reduced biomass observed following atn deletion. In streptococcal
species, biofilm production and bacterial colonization of abiotic surfaces are decreased
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with disruption of srtA and genes encoding SrtA-dependent cell wall proteins161,162. The
enterococcal housekeeping sortase (SrtA) is a biofilm-promoting factor. In contrast to
previous reports for E. faecalis106, deletion of srtA, in the present study, severely
hampered adherence to plastic substrata and subsequent biofilm growth, especially under
hydrodynamic conditions. These observations corroborate findings of Kristich et al. 109 in
which transposon-mediated disruption of srtA results in approximately 30% decreased
biofilm biomass compared to the parental strain using the microtiter biofilm assay.
Together, these findings argue that SrtA plays a critical role in biofilm development in E.
faecalis, especially in presence of shear forces. Sortase-dependent substrates have diverse
functions ranging from adhesion and biofilm formation to immune evasion during
pathogenesis163,164. LPXTG surface proteins, including aggregation substance (AS), the
enterococcal surface protein (Esp), the endocarditis and biofilm-associated pilus (Ebp), a
member of the microbial surface component recognizing adhesive matrix molecules
(MSCRAMMs) (ace), and the recently characterized EF3314, are the most studied
proteins in E. faecalis and E. faecium. They mediate binding to host extracellular matrix
proteins such as collagen and fibrinogen and promote enterococcal biofilm formation and
virulence in animal models of enterococcal pathogenesis, including endocarditis and
UTI145,150,165-169. Sortases and sortase substrates are thus attractive drug targets given that
most of these cell wall proteins are involved in bacterial virulence. However, since srtAdeficient mutant biofilm are sensitive to DNase I treatment, it is unlikely that this gene
plays a role in DNA release.
DNA release occurs from autolytic processes or competence induction in
bacteria121,126,151. Freeze-dry electron micrographs in this study reveal extracellular fibers
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protruding from lysed cells present in enterococcal biofilms. The findings reported here
demonstrate that Atn is involved in DNA release during the accumulative phase of
biofilm development in E. faecalis. This is in agreement with several reports highlighting
the contribution of autolytic processes during biofilm formation121,170,171. Recently, the
enterococcal proteases GelE and SprE, both under positive regulation of the fsr quorum
sensing signaling, were shown to contribute to biofilm formation by regulating cellular
autolysis104. GelE mediates DNA release during planktonic and biofilm modes of growth,
in contrast to SprE, which acts as a negative regulator of autolysis and biofilm
production. It is thus postulated that during biofilm formation fratricidal mechanisms
underlie cell death and DNA release, which may result from the interactions between
GelE and Atn103,121. However, certain E. faecalis laboratory and clinical strains, including
OG1X further discussed in the second chapter of this dissertation, are able to produce
biofilms in the absence of GelE172, implying that E. faecalis may also employ GelEindependent DNA-dependent or independent mechanisms for biofilm formation.
Atn-mediated DNA release occurs at a specific time during the biofilm process.
This finding implicates a temporal regulation of DNA release during biofilm formation.
DNA release may occur in response to a particular cell density. It is possible that upon
reaching critical mass following initial attachment, E. faecalis activates the fsr-quorumsensing signaling pathway and the expression of autolytic factors, such as GelE and SprE.
GelE cleavage of Atn, shown to occur in vitro103, may then induce Atn-mediated cell
death in a subpopulation103 leading to DNA release and biofilm maturation and
stabilization.
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However, the ability of atn-deficient strains to produce DNA-dependent biofilms,
albeit in a delayed fashion, is consistent with slower accumulation of eDNA from the
actions of other autolytic factors in E. faecalis134,173. Mesnage et al. characterized two
additional peptidoglycan hydrolases, AtlB and AtlC, in the JH2-2 strain of E. faecalis,
which they showed to have compensatory functions in cell separation and autolysis in the
absence of the major N-acetylglucosaminidase, AtlA or Atn134. It is likely that DNA
release is the result of the synergistic activities of these autolytic enzymes during the
establishment of E. faecalis biofilms. Further research is thus warranted to identify the
regulatory pathway leading DNA release during biofilm formation.
Biofilm formation is a complex and highly regulated process involving a
combination of genetic and environmental factors critical for specific developmental
stages174. The present study uncovered a critical function for SrtA and provided strong
evidence for the role of Atn in DNA release and biofilm production. Further research is
required to identify SrtA-dependent proteins important for biofilm formation, in addition
to those already characterized and involved in biofilm production, adherence to host cells
and virulence in several models of enterococcal infections166-169,175,176. As an
opportunistic pathogen, it is conceivable that E. faecalis employ several mechanisms to
establish biofilms. eDNA is a critical component of the extracellular matrix of DNAdependent

biofilms

produced

by E.

faecalis

as

well

as E.

faecium and E.

gallinarum clinical isolates (data not shown). eDNA is crucial for maintaining the
architectural integrity and the stability of enterococcal biofilm. The events mediating
DNA release, localization, and interactions with other components of this protective
structure require further investigation. Identifying the components and the regulatory
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network of the extracellular matrix of enterococcal biofilms will be of great importance
in the eradication of these pathogens.
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CHAPTER TWO
BIOFILM FORMATION IS CRITICAL FOR ENTEROCOCCAL VIRULENCE
IN AN OPTIMIZED MURINE MODEL OF FOREIGN BODY-ASSOCIATED
URINARY TRACT INFECTIONS
Modified from:
Guiton, P.S., et al. (2009) Infect Immun. and
Guiton, P.S., et al, manuscript in preparation
ABSTRACT
Catheter-associated urinary tract infections (CAUTIs) constitute the majority of
nosocomial UTIs and pose significant clinical challenges. The insertion and presence of
urinary catheters elicit major histological and immunological changes that render the
bladder susceptible to microbial invasion, colonization, and dissemination. Enterococcal
species are among the predominant causative agents of CAUTIs. However, very little is
known about the pathophysiology of enterococci-mediated UTIs. This study optimizes a
rodent model of foreign body-associated UTI in order to mimic conditions of indwelling
urinary catheters in patients. Studies in this model uncover valuable details of the
molecular constituents of foreign body-induced inflammatory responses and demonstrate
their ineffectiveness against E. faecalis in catheterized animals. Enterococcal biofilm
formation on the foreign body in vivo is essential for the establishment of persistent UTIs
in the face of the massive inflammatory response ensuing from urinary implantation.
Notably, only a subset of enterococcal in vitro biofilm-promoting factors, including
sortases, is critical for biofilm formation and urovirulence. Overall, this murine model
represents a significant advance in the understanding of CAUTIs and underscores the
contribution of urinary catheterization to E. faecalis uropathogenesis. It is also a valuable
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tool for the identification of biofilm and virulence determinants that can serve as potential
antimicrobial targets for the treatment of enterococcal infections.
INTRODUCTION
Urinary catheterization is the primary cause of 80% of hospital-acquired UTIs177.
The insertion and presence of indwelling urinary catheters disrupts the normal
mechanical and host defenses of the urinary tract, allows extracellular microbes access
into the sterile environment of the bladder by ascending through the catheter lumen or
from the urethral meatus along the catheter, and provides an additional surface for
biofilm formation and the establishment of persistent infections30,32-36,178,179. Even in the
absence of microbial colonization, urinary catheterization is associated histological and
immunological alterations in the bladder, including bladder wall edema, inflammatory
cytokine production, immune cell infiltration, and mucosal lesions of the bladders and
kidneys

26-30

which can lead to bladder cancers180,181. However, the molecular

mechanisms underlying these responses require further research. The high incidence rate
coupled with the medical and economic hurdles associated with catheter-associated
urinary tract infections (CAUTIs) underscore the need for a better understanding of
CAUTI pathogenesis.
Enterococci, infrequently associated with community-acquired UTIs, play a
prominent role in the pathogenesis of CAUTIs56. E. faecalis is among the predominant
pathogens isolated from polymicrobial communities on the surface of indwelling urinary
catheters and biliary stents182-186. However, the mechanisms underlying E. faecalis
uropathogenesis are poorly defined. Several rodent models have been developed to
investigate E. faecalis pathogenesis in the urinary tract in single and mixed infections
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with other Gram-negative pathogens105,187-191. These models involve the transurethral
inoculation of low to high volumes of bacterial suspensions (50 to 200µl containing 107
to 108 CFU bacteria) into the bladders of healthy or streptozocin-induced diabetic
animals191. The experimental conditions defined by these models are primarily useful for
the study of E. faecalis-mediated pyelonephritis, but are inadequate for the investigation
of persistent enterococcal CAUTIs as the bacteria are readily cleared from the bladder
and fail to establish chronic cystitis105,190,191. Nonetheless, findings obtained from studies
in these models have implicated several enterococcal factors in UTI pathogenesis,
including the enterococcal surface protein Esp105, the enterococcal biofilm and pilusassociated sortase C (SrtC or bps)106, and the endocarditis and biofilm-associated pilus
(Ebp)145. However, well-characterized adhesins and biofilm determinants often associated
with enterococcal UTI isolates192,193 such as the aggregation substance (AS) and the
housekeeping sortase (SrtA)108,109, were reported to be dispensable for virulence in the
urinary tract106,108. Since these conclusions were drawn from models where persistent
infections cannot be established, it is imperative to re-examine the existing paradigm in
an animal model that better mimics the transition of E. faecalis from a commensal to a
virulent pathogen in the urinary tract.
This present study reports the optimization and use of a rodent model of foreign
body-associated UTI developed in rats by Kurosaka et al.29 and adapted in mice by
Kadurugamuwa et al.194 to investigate the pathophysiology of enterococcal CAUTIs. The
report details unappreciated characteristics of the physiological changes in the bladder
ensuing from urinary implantation. Findings from this murine model substantiate the
allegations that biofilm formation is a major enterococcal virulence factor that is critical
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for the establishment of persistent cystitis and pyelonephritis. Of the enterococcal in vitro
biofilm determinants examined thus far, the enterococcal sortases and pili, as well as the
enterococcal enhanced expression of pheromone (Eep) metalloprotease and the
transcription factor AhrC from the ArgR family, contribute to uropathogenesis in
catheterized animals whereas the autolytic factors GelE and Atn are dispensable. This
optimized murine model is thus well suited to identify host and enterococcal factors
critical for pathogenesis in the urinary tract and will provide a better understanding of the
mechanisms underlying the pathophysiology of CAUTIs.
RESULTS
Part I: Optimization and characterization of the murine model of foreign bodyassociated UTIs.
Urinary implantation elicits severe histological changes in the murine bladder akin to
observations in human urinary catheterization. In order to study the pathophysiology of
CAUTI associated with the presence of urinary catheters, 4-5mm long pieces of silicone
tubing (implant) were transurethrally introduced into the bladders of seven to eight week
old C57BL/6Ncr female mice as described in the Materials and Methods section and
illustrated on Fig. 14. Silicone was chosen instead of polyethylene tubing29 as it is the
most common material used in All Silicone Foley urinary catheters in humans195,196. The
recovery of silicone implants inside the murine bladders on the day of animals sacrifice
was greater than 95% at 24h and approximately 75% seven days following implantation
(data not shown). The data presented here represent animals with bladder implant at the
time of sacrifice.
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Figure 13: Schematic of transurethral urinary implantation.
Silicone implant is transurethrally introduced in the murine bladder by pushing a
section of polyethylene tubing (PE) into the urethra with the help of tweezers.
The silicone implant can remain in the bladder at least 7 days post implantation.
Adapted from Reference 29.

Compared to non-implanted animals (Fig.15A and D), histological analyses of
H/E stained bladder sections 24h post implantation reveal mucosal hyperplasia,
submucosal edema with polymorphonuclear leukocyte (PMN) infiltration into the lamina
propria and epithelium, and urothelial sloughing in implanted animals (Fig.15B and E).
Damage to the uroepithelium in implanted bladders was also observed by
immunofluorescence microscopy using anti-uroplakin III antibody, which stains the
luminal surface of the terminally differentiated superficial umbrella cells of the bladder.
Comparison of bladder sections at 24 h post implantation showed discontinuity of
uroplakin staining of implanted bladders (Fig. 15H) versus continuous epithelial staining
of non-implanted bladders (Fig. 15G), indicating the loss of superficial umbrella cells in
the former. These data suggest that implantation with a foreign body elicits major
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architectural changes in the bladder associated with activation of the host immune
response.

Figure 14: Implantation-mediated histological changes are associated with enterococcal
colonization of the murine bladder.
(A-F) H/E staining of bladder sections from PBS-treated non-implanted (A, D), PBS-treated
implanted (B, E), or OG1RF infected implanted (C, F) mice 24 hpi observed under light
microscope at 40X (A-C) and 63X (D-F) magnifications. Arrow in (E) indicates damage to the
uroepithelium.

U=uroepithelium,

LP=lamina

propria,

L=lumen,

M=muscularis.

(G-I)

Representative CLSM images of the sections from the same animals as in (A-F) immunolabeled
with goat anti-mouse uroplakin III (green), rabbit anti-Lancefield Group D antigen (red), and
counterstained with TOPRO-3 nuclear dye (blue). Dashed line separates the lumen (L) from the
uroepithelium surface (U). Scale bar =10µm.

Implant-mediated bladder edema and vascular permeability occurs independently of
the neurogenic inflammatory pathway. The onset of bladder wall edema, classic
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consequence of urinary catheterization in humans30, was further assessed by bladder
weight determination at 3, 6, 9, 12, 18, and 24h post implantation and compared to nonimplanted animals. The murine bladder of implanted animals significantly increases in
weight as early as 3h post implantation (p=0.0011 by the Mann Whitney U test) and
reaches approximately 60mg by 24h (Fig.16A). Histological analysis of H/E stained
bladder tissue sections from implanted animals at each time point depicts the gradual
progression of bladder wall edema over time, corroborating the significant increase in
bladder weight (Fig. 16B). The implant-induced edema can be attributed to plasma
protein extravasation (PPE) in the tissue as assessed by Evans blue extravasation assay
performed 6h post implantation (Fig. 16C). Approximately 60µg of Evans blue per gram
of bladder tissue was extravasated and recovered from implanted bladders following
intravenous injection in the murine tail vein, a significantly higher amount compared to
40µg/g from non-implanted controls (p=0.0348).
Bladder wall edema and vascular permeability are hallmarks of the neurogenic
inflammatory pathway in the urinary tract in response to chemical irritants such as
cyclophosphamide,

capsaicin,

and

bacterial

endotoxin197,198.

The

neurogenic

inflammatory pathway is activated in response to the stimulation of sensory neurons
innervating the bladder and the release of proinflammatory neuropeptides such as
substance P, neurokinin A, and calcitonin gene-related peptide (CGRP)197, which induces
edema, neutrophil infiltration, the formation of reactive oxygen species, and contribute to
pain197,198. This neurogenic inflammation can be inhibited by administration of specific
small molecules inhibitors, including CP-99,994 and CP-96,345 which are specific
neurokinin 1 receptor (NK1R) antagonists199-202, aminoguanidine (AG) which is an

45

irreversible inhibitor of the inducible nitric oxide synthase (iNOS)203-205, and alfuzosin
which is an antagonist of alpha 1 adrenoreceptors present on the surface of sensory
neurons206. To assess the contribution of the neurogenic inflammatory pathway in
implant-induced edema, animals were treated with CP-99,994 or CP-96,345 (5-10mg/kg,
i.p. or i.v.) and AG (200mg/kg, i.p.) administered respectively 30 min and 1h prior to
implantation. A second dose of each compound was given 3h post implantation and PPE
was assessed 6h post implantation. Phosphate buffered saline (PBS) or appropriate
vehicle control was administered in the same manner as in the treatment group. No
inhibitory effects were observed following treatments with neurogenic pathway
inhibitory chemicals. PPE occurs at similar levels (~60ug/g) in compounds-treated
implanted animals and vehicle-treated implanted animals (Fig.16C). Likewise, these
treatments do not alter the increase in bladder weight post implantation (data not shown).
Similar to the NK1R and iNOS inhibitors, preliminary evidence suggests that treatment
with alfuzosin (60µg/kg, i.v.) does not prevent bladder weight increase nor inhibit
vascular permeability in implanted bladders (data not shown). Additionally, no detectable
levels of SP, the NK1R ligand that induces neurogenic inflammation, could be detected
by mass spectrometry in implanted animals for 3h (data not shown). Immunofluorescence
microscopy of implanted and non-implanted bladders at 6h and 24h stained with
antibodies raised against SP and NK1R reveal no major changes in the expression or
localization of these two mediators of neurogenic inflammation (data not shown).
Together, these findings indicate that the NK1R-induced neurogenic inflammation is not
a major contributor in the onset of bladder wall edema and vascular permeability.
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Figure 15: Urinary implantation induces edema and plasma protein extravasation.
(A) Bladder weights of non-implanted (control) and implanted (+)at the indicated time (B ) H/E
staining of bladder sections from non-implanted and implanted animals at indicated time points
observed under light microscope at 10X magnification. (C) Plasma protein leakage in bladder
tissue determined by Evans blue content at 6hpi in non-implanted animals treated with saline and
implanted animals treated with saline, dexamethasone (10mg/kg, i.p.), aminoguanidine (AG, 2
doses of 200mg/kg i.p.), CP99994 (2 doses 5mg/kg, i.p.). (D) Bladder weights at 24hpi of nonimplanted and implanted mice in presence or absence of E. faecalis OG1RF strain. Graphs
represent the mean of each dataset from at least two independent experiments; Error bars=SEM;
*p<0.05, ns: p>0.05 by the Mann Whitney U test.

Urinary implantation leads to the upregulation of specific inflammatory markers and
the specific recruitment of myeloid-derived cells in the murine bladder. To identify the
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soluble and cellular constituents of the bladder immunological responses to the silicone
implant, multiplex bead arrays and flow cytometry assays were performed on bladder
homogenates and suspensions in non-implanted and implanted animals at 24h post
implantation.

Of the 23 cytokines examined, only interleukin 6 (IL-6), G-CSF

(Granulocyte-Colony Stimulating Factor), and KC (Keratinocyte-derived Cytokine) were
consistently present in implanted bladder homogenates at least two-fold above the levels
of non-implanted animals at 24 hpi (Fig. 17). Conversely, GM-CSF (Granulocyte
Monocyte-Colony Stimulating Factor) and MIP-1α (Macrophage Inflammatory Protein 1
alpha) showed at least two fold decreased expression in implanted animals compared to
non-implanted animals 24 hpi (Fig. 17). Flow cytometry experiments reveal that
CD11b+Gr1+ myeloid cells account for approximately 15% of the live population in
implanted animals compared to 1% in non-implanted controls (p<0.0001; Fig.18A). No
difference was observed in lymphocyte numbers in presence or absence of implant at
24hpi (Fig. 18A). Specific markers were used to further specify the myeloid cells. This
analysis reveals a 1-2 log increase in eosinophils (SiglecF+), basophils (FccR1+), and
monocytes (CD11b+Ly6G-Ly6C+) specifically in implanted animals (Fig.18B).
Additionally, macrophages (CD11b+F4/80+MHCII- and CD11b+F4/80+MHCII+) are
present with approximately 1 and 1.5 log, respectively, over non-implanted controls (Fig.
18B). Neutrophils (CD11b+Gr1+Ly6GhiLy6Clo) are the most abundant immune cells
recruited in response to urinary implantation with approximately 3 log more cells relative
non-implanted controls (Fig. 18B). Further studies using an antibody raised against the
neutrophil-specific receptor NB1 (also known as CD177)207 corroborates the above
findings that PMNs are the major immune infiltrates in implanted murine bladders (data
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not

shown).

There

was

no

change

in

the

number

of

dendritic

cells

(CD11b+CD11c+MHCII+/-) or mast cells (cKit+) present in implanted animals compared
to non-implanted controls (data not shown). Together, these results indicate that the
silicone implant elicits a specific inflammatory response in the bladder characterized by
the up-regulation of pro-inflammatory cytokines and myeloid infiltrates.

Figure 16: Cytokine profiles following urinary implantation with and without enterococcal
challenge.
Graph represents whole bladder cytokine expression of implanted animals inoculated with PBS
(gray bars) or OG1RF (black bars) at 24 hpi. Cytokines reported are expressed with at least twofold difference relative to non-implanted controls. Data from a representative experiment of 4
independent experiments with n=5mice/condition/experiment. Error bars =SEM. *p<0.05, pvalue by the Mann Whitney U test.
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Figure 17: Neutrophils are important cellular infiltrates during enterococcal CAUTI.
Cellular infiltrates from non-implanted (white bars), implanted (black bars), or implanted and
infected with E. faecalis OG1RF (gray bars) at 24hpi derived from flow cytometry analysis. Nonactivated and activated macrophages (CD11b+F4/80+MHCII- and CD11b+F4/80+MHCII+,
respectively), neutrophils (CD11b+Ly6GhiLy6Clo), monocytes (CD11b+Ly6G-Ly6C+), eosinophils
(SiglecF+), and basophils (FccR1+). Data are the mean derived from at least two independent
experiments with n=3-5/experiment/condition; Error bars represent SEM; *p<0.05, **p<0.005,
***p<0.0005 value by the Mann Whitney U test.
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Part 2: Enterococcal biofilm formation and virulence following urinary
implantation
E. faecalis establishes persistent infections in the bladders and kidneys in an optimized
murine model of CAUTI. In order to study the pathophysiology of E. faecalis-mediated
CAUTIs, mice were inoculated with 1-3.5x107 CFU of E. faecalis strain OG1RF by
transurethral catheterization immediately following urinary implantation. In mockinfection studies with PBS, no bacteria were recovered from implants or organs (data not
shown). At 24-hour post infection (hpi), OG1RF is recovered from the implants with a
median of 9.76x105 CFU/ml (Fig. 19A). Bacterial titers on the abiotic surfaces increase
significantly over the course of the infection (7 days) to a median of 8.64x106 CFU/ml
(Fig. 19A). In implanted animals, OG1RF reaches a median titer of 3.2x106CFU/ml 24
hpi in the bladders, which is significantly higher (p=0.0011) than bacterial titers
(2.7x103CFU/ml) recovered from the bladders of non-implanted animals (Fig. 19B).
Similarly, bacterial titers from the kidneys increase significantly from 24 hpi to 7 dpi in
implanted animals (Fig. 19C). OG1RF was readily cleared from the bladders and the
kidneys within 48 hpi in the absence of implants (Fig. 19B-C). In addition, bacterial titers
are significantly lower in tissues derived from animals that have lost their implants during
the course of infection compared to tissues with retrieved implants (Fig. 20), with the
exception of bladder titers at 48 hpi (p=0.0737) and kidneys titers at 72 hpi (p=0.130)
(Fig. 21). These data suggest that the presence of the implants contributes to increased
bacterial colonization and persistence in the urinary tract.
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Figure 18: E. faecalis establishes persistent colonization of silicone implants, bladder, and
kidneys in a murine model of CAUTI.
(A) Bacterial titers on logarithmic scale (log scale) from silicone implants retrieved from
female C57Bl/6Ncr mice infected with OG1RF for 24, 48, 72 hpi, and 7 dpi. (B-C) Graphs
represent bacterial titers from homogenized bladders (B) and kidneys (C) from non-implanted
(○) or implanted (●) of animals infected with OG1RF for 24, 48, 72 hpi, or 7 dpi. Horizontal
dashed lines represent the limit of detection for viable bacteria. Each symbol represents a mouse
from two independent experiments with n=5/condition. The horizontal bars represent the
median of each dataset; *p<0.05, **p<0.005, and ***p<0.0005 by the Mann Whitney U test.
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Figure 19: Implant loss from murine bladders correlates with lower bladder and kidney
infection.
Graphs represent bacterial titers in log scale recovered from the bladders (A) and the kidneys (B)
of animals that have lost the implants (L-○) or retained the implants (R-●) at the indicated time of
sacrifice. Experiment was done at least 3 times with n=5/experiment. The horizontal dotted line
depicts the limit of detection. The horizontal bar represents the median of each dataset, *p<0.05,
**p<0.005, ns = p>0.05 by the Mann-Whitney U test.

E. faecalis produces biofilm on the surface of the silicone implant in vivo.

To

determine whether bacteria recovered from silicone implants are within biofilms, we
examined 15 implants retrieved 72 hpi from murine bladders from three independent
experiments by scanning electron microscopy (SEM). In mock-infection, the implants
were coated on the outside and in the lumen with host factors found in the urine as
previously reported208 (data not shown). A similar film appears on 12 implants retrieved
from animals infected with OG1RF. In approximately 70% of the silicone implants
retrieved from infected animals, bacteria are readily observed in clumps both on the outer
surface (Fig. 21A-B) or filling the entire lumen (Fig. 21C-F). The coccoid
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microorganisms are embedded in a thick extracellular matrix (Fig. 21E-F). The reason for
the absence of biofilms from the remaining implants is not certain, but could be attributed
to sample processing prior to visualization since those animals also exhibited
significantly enhanced infection in the bladders and kidneys. These findings indicate that
enterococcal biofilms are produced in vivo on indwelling silicone material during the
course of the infection.

Figure 20: E. faecalis produces biofilms on the surface of silicone implants in vivo.
Representative scanning electron micrographs of silicone implants retrieved from murine
bladders infected with OG1RF at 72 hpi showing bacterial biofilms on the outer surface (A-B)
and the filling the lumen (C-F) of the silicone implant. Bacteria (white arrowhead) are often
associated with host cells, indicated by black arrowhead in (C). Both bacteria and host immune
cells can also be found embedded in a thick extracellular material, indicated by arrow, in the
lumen of the silicone implant 72 hpi (E-F). Areas in the black box on (A, C, E) are magnified in
(B, D, F). Scale bars in µm: 20 (A, C), 5 (B, D, F), and 100 (E).
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E. faecalis enhances the inflammatory response in implanted animals. The histology
of the uroepithelium of implanted bladders following infection with E. faecalis OG1RF is
similar to that of mock-infected implanted animals in that the bladder remains edematous,
distended, and sometimes hemorrhagic (Fig.15C and F). In contrast, non-implanted
bladders infected with OG1RF show no major histological changes and appear similar to
the bladders of mock-infected non-implanted controls (data not shown), in agreement
with previous reports with other E. faecalis strains190. Immunolabeling of E. faecalis with
antibody against the Lancefield streptococcal group D antigen in histology sections show
bacterial staining in the bladder lumen of infected animals with implants (Fig. 15I). E.
faecalis is also found in association with the surface of the uroplakin-positive and
uroplakin-negative uroepithelium and occasionally found in the submucosal areas (Fig.
22). In contrast, very few bacteria were observed in the bladders of non-implanted
animals 24 hpi (data not shown). No labeling was observed in mock-infected animals
with or without implants (Fig. 15G and H), reaffirming the specificity of the antibody
staining. Furthermore, enterococcal challenge does not affect murine bladder weight in
presence or absence of urinary implants, as shown in Fig. 16D. The presence of E.
faecalis slightly enhances the expression of IL-6, IL-12(p40), G-CSF, and KC and
specifically induces the production of IL-1β and MIP-1α (back to non-implanted levels)
in implanted animals compared to implanted mock-infected controls (Fig. 17). E.
faecalis OG1RF infection of non-implanted animals results in no significant changes in
the expression of the cytokines tested compared to mock infection (data not shown).
Similar to uninfected implanted animals, CD11b+Gr1+ myeloid cells are the majority of
cellular infiltrates at 24h in implanted animals with E. faecalis infection (Fig. 18A). They
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account for approximately 30% of live populations in these animals, significantly higher
than implanted controls in the absence of E. faecalis (p<0.00001). This increase in
myeloid cells in presence of E. faecalis is primarily due to the recruitment of neutrophils
with a significant increase of approximately 1 log over mock-infected implanted controls
(p<0.001) (Fig.18B). Interestingly, similar numbers of macrophages, monocytes,
basophils, and eosinophils are present in the bladders of implanted animals even in
presence of E. faecalis (Fig. 18B), indicating that recruitment and activation of these
immune cells occur specifically in response to the silicone implant. There are no
significant changes in the number of dendritic cells (CD11b+CD11c+MHCII+/-) present in
implanted animals compared to non-implanted controls even in presence of E. faecalis
(data not shown).

Figure 21: E. faecalis localization in implanted animals.
Representative CLSM images of bladder sections from implanted mice infected with OG1RF 24
and 72hpi immunolabeled with antibodies against uroplakin III (green), Lancefield Group D
antigen (red), and counterstained with TOPRO-3 nuclear dye (blue). Bacteria are present in the
bladder lumen (A), uroepithelial surface (B), and areas denuded of uroplakin staining (C). Scale
bar =28µm (A) 5µm (B) and 14 µm (C).
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Part 3: Relative contributions of known biofilm determinants to E. faecalis
uropathogenesis
To assess the role of biofilm formation in enterococcal colonization of and persistence in
the urinary tract, implanted animals were infected with OG1RF, a gelatinase-defective
strain OG1X, or OG1RF isogenic in frame deletion mutants of known biofilm
determinants.
E. faecalis biofilm formation and virulence in the urinary tract occur independently of
autolytic factors. OG1X is a nitrosoguanidine-induced gelatinase (gelE)-defective mutant
of the oral isolate OG1, the same parental strain as OG1RF209. Despite OG1X defect in
gelatinase production, this strain produces biofilms to a similar extent as OG1RF on PVC
coverslips in TSBG at 37ºC under static conditions as determined by crystal violet
staining-based quantification (Fig. 23A). Notably, OG1X biofilms are also sensitive to
DNaseI treatment under these conditions. Yet, when introduced in implanted animals,
OG1X is recovered at significantly lower CFU than OG1RF from implants and bladders
(p<0.0001) and is unable to ascend to the kidneys following urinary implantation 24hpi
(Fig. 23B), indicating a severe attenuation in urovirulence. This observation led to the
hypothesis that GelE may be necessary for virulence in the urinary tract. However,
infection of implanted animals with an OG1RF isogenic gelE-deficient strain
(OG1RF∆gelE) causes similar colonization patterns as the parental strain (Fig. 23C), with
slightly (albeit significant, p=0.0002) higher bacterial titers recovered from implants
24hpi. Furthermore, deletion of the major autolysis atn critical for DNA release during in
vitro biofilm formation does not affect virulence in this murine model up to 7 days post
infection (Fig. 23D and data not shown). Together, these data indicate that the autolytic
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factors GelE and Atn (see chapter one) are dispensable for enterococcal virulence and
OG1X may harbor additional mutations in genes required for urovirulence.

Figure 22: GelE and Atn are dispensable for enterococcal virulence in implanted animals.
(A) Comparison of OG1RF and OG1X biofilm formation on PVC coverslips in presence and
absence of 5µg/ml of DNaseI in TSBG at 37ºC for 24h. n=3 independent experiments. Error
bars=SEM (B-D) Graphs represent CFU enumeration of OG1RF, OG1X, OG1RF isogenic inframe gelE- and atn-deficient mutants recovered from retrieved implants, bladders and kidneys
24 hpi with each strain. Horizontal dashed lines represent the limit of detection for viable
bacteria. Each experiment was performed in duplicate n=4-5/strain/experiment. The horizontal
bars represent the median of each dataset; *p<0.05; ***p<0.0005, ns = p>0.05 by the Mann
Whitney U test.
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Both enterococcal sortases contribute to implant and urinary tract colonization.
The housekeeping and pilus-associated sortases, SrtA and SrtC respectively, are
important mediators of biofilm formation106,109,210. Additionally, deletion of srtC results
in attenuation of E. faecalis virulence in a murine model of ascending UTIs106. In contrast
to GelE and Atn, infection of implanted mice with srtA-deficient OG1RF strain
(OG1RFΔsrtA) causes a 105-fold decrease in bacterial titers recovered from the implants
(Fig. 24A) and an approximately 103 decrease in CFUs from both bladders and kidneys
compared to wild type infection (Fig. 24B-C). This defect can be partially rescued by
ectopic expression of a wild type copy of srtA in OG1RFΔsrtA. The complemented strain
OG1RFΔsrtA/srtA (OG1RFΔsrtAc) is recovered at levels similar to wild type titers from
the implants and organs (Fig. 24A-C). The lack of full complementation is not entirely
understood, but may be due to plasmid loss during infection based on higher colony
counts in the absence of selective antibiotic. A similar attenuation in virulence is
observed upon deletion of srtC (Fig. 24A-C) whereby OG1RFΔsrtC is recovered at
significantly lower titers from the implants (p=0.0017), the bladder, and the kidneys
(p<0.0001 and p=0.0031, respectively) compared to wild type OG1RF. Similar findings
are observed at 48 hpi (data not shown). Scanning electron micrographs reveal very few
OG1RFΔsrtA cells present on the surface or in the lumen of retrieved implants 72 hpi in
contrast to the complemented strain, the atn-deficient, or wild type strains that heavily
colonize the implants (Fig. 24D). These results indicate that contrary to GelE and Atn,
SrtA and SrtC or more specifically, SrtA-dependent substrate(s) and the enterococcal
pilus (Ebp) (data not shown), are involved in biofilm production and necessary for full
virulence in the urinary tract of implanted animals.
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Figure 23: Sortase A is critical for implant colonization and virulence in the urinary tract.
(A-C) Graphs represent bacterial titers from retrieved implants (A), homogenized bladders (B),
and kidneys (C) from implanted mice infected for 24 hrs with OG1RFwt (●), OG1RFΔsrtC(◊)
OG1RFΔsrtA (□), or OG1RFΔsrtA/srtA (■). Horizontal dashed lines represent the limit of
detection for viable bacteria. Each symbol represents a mouse and each experiment was done at
least twice with n=5/strain. The horizontal bars indicate the median of each dataset; *p<0.05,
**p<0.005, ***p<0.0001, and ns for p>0.05 by the Mann Whitney U test. (D) Representative
scanning electron micrographs of silicone implants retrieved from murine bladders 72 hpi with
OG1RFwt, OG1RFΔsrtA, OG1RFΔsrtA/srtA (ΔsrtAc), and OG1RFΔatn. Scale bars = 5µm for
OG1RFwt, OG1RFΔsrtA, and OG1RFΔsrtAc; 2.5µm for OG1RFΔatn.

Eep and AhrC contribute to E. faecalis pathogenesis in the urinary tract. The
enterococcal enhanced expression of pheromone (Eep) protein is a metalloprotease
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involved in the processing of sex pheromones during conjugation211,212. RIVET screens
identified the eep locus as one of several transcriptionally upregulated promoters during
E. faecalis biofilm formation in vitro and in	
  vivo114,213. Furthermore, in-frame deletion of
eep in OG1RF in the absence of all conjugative plasmids results in significant virulence
attenuation in a rabbit model of endocarditis, indicating this metalloprotease also has a
role in virulence that is unrelated to conjugation/sex pheromones (Frank, K.L. et al,
unpublished and personal communication).

Preliminary evidence suggests that

OG1RF∆eep has altered biofilm architecture relative to the parental strain (Frank, K.L.,
et al, unpublished and personal communication). Similarly, transposon insertion in
ef0983, a locus encoding a member of the ArgR family of transcription factors (ahrC),
results in biofilm defects109 and virulence attenuation in the rabbit model of endocarditis
(Frank K. L. et al, unpublished and personal communication), involving AhrC as a
biofilm-promoting and enterococcal virulence factor. The contributions of Eep and AhrC
to enterococcal uropathogenesis were assessed using the murine model of foreign bodyassociated UTI. OG1RF∆eep and OG1RFΩef0983 were introduced in implanted animals
and bacterial titers were assessed 24hpi and compared to the parental strain. Both strains
are recovered at significantly lower titers from implants and kidneys compared to the
parental strain (p<0.05 in all cases) (Fig. 25). However, whereas no defects were
observed in bladder colonization with OG1RF∆eep (p>0.05), OG1RFΩef0983 was
significantly attenuated in the bladder (p=0.0003) as shown on (Fig. 25) (Frank, K.L.,
Guiton, P.S., et al, manuscript in preparation). Together, these findings indicate that both
genes contribute to urovirulence and furthermore underscore the usefulness of the
optimized murine model of CAUTI for the identification of novel virulence factors
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specifically involved in enterococcal colonization of the urinary tract that are also critical
for other enterococcal diseases.

Figure 24: Eep and AhrC promote enterococcal uropathogenesis
Graph represents bacterial titers from retrieved implants, homogenized bladders,
and kidneys from implanted mice infected for 24 hrs with OG1RF (●), OG1RFΔeep
(■) OG1RFΩEF0983 (▲). Horizontal dashed lines represent the limit of detection
for viable bacteria. Each symbol represents a mouse and each experiment was done
at least twice with n=5/strain. The horizontal bars indicate the median of each
dataset; *p<0.05, ***p<0.0005, and ns for p>0.05 by the Mann Whitney U test.

Part 4. Role of implant-mediated inflammation during E. faecalis pathogenesis in
the urinary tract
Induction of bladder inflammation is not sufficient for the establishment of successful
E. faecalis infection without a foreign body. To address the effects of implant-mediated
inflammation on enterococcal infection, animals were implanted for 24h prior to infection
62

with E. faecalis OG1RF strain and bacterial titers from the implant and organs were
compared to titers recovered from animals implanted and simultaneously infected. As
shown on Fig. 26A, E. faecalis is able to colonize the implants and organs of preimplanted animals to similar levels as the control group, indicating that E. faecalis is
resistant to the implant-induced inflammatory response, which does not enhance nor
prevent enterococcal colonization.
Furthermore, to assess whether any type of cystitis predisposes the bladder to E.
faecalis infection in the absence of foreign body, murine hemorrhagic cystitis was
induced via treatment with cyclophosphamide (CYP) (150kg/mg, i.p.). CYP-induced
cystitis is a well-characterized model of bladder inflammation and involves among
others, the induction of the neurogenic inflammatory pathway described above198,214.
Even though implant-mediated inflammation occurs independently of the neurogenic
inflammatory pathway, it shares some commonalities with CYP-induced cystitis such as
bladder wall edema, mucosal damage, and neutrophil infiltration203,204,215,216 (Fig. 26B).
E. faecalis introduced in non-implanted CYP-treated animals are rapidly cleared from the
urinary tract similar to saline-treated non-implanted controls at 6hpi (Fig. 26C). By
24hpi, bacteria are recovered at very low levels (102-103 CFU/ml in organs) from both
experimental groups compared to implanted animals whose organs remain colonized at
very high titers (105-106CFU/ml in organs as well as implant; data not shown). Together,
these findings indicate that the inflammatory state of the bladder is not sufficient to
promote E. faecalis infection of the urinary tract in the absence of a foreign body.
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Figure 25: Inflammation is not sufficient enterococcal urinary tract colonization
(A) CFU enumeration of OG1RF from implant, homogenized bladders and kidneys of animals
pre-implanted (Pre-imp) 24h prior to or implanted (imp) on the day of bacterial challenge. (B)
H/E staining of bladder sections of 6 h cyclophosphamide (CYP)-treated or implanted mice
observed under light microscope, magnification 20X. Experiment was performed in duplicate
with n≥3-5/group. (C) Graph represents OG1RF titers at 6hpi from retrieved implants,
homogenized bladders, and kidneys from non-implanted CYP- or saline-treated and implanted
(Imp) animals. For (A) and (C) The horizontal bars indicate the median of each dataset. Two
independent experiments performed with n=5-10/condition/experiment.

*p<0.05, **p<0.005

value by the Mann Whitney U test.

Glucocorticoid treatment partially inhibits implant-induced inflammation and
enhances E. faecalis urovirulence. Since induction of bladder inflammation does not
alter the pathogenesis of E. faecalis, further experiments were performed in implanted
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animals in presence of an anti-inflammatory and immunosuppressive agent to further
assess the role of implant-induced inflammation during enterococcal CAUTI.
Dexamethasone, a well-characterized glucocorticoid, was administered in mice at a
concentration of 10mg/kg, i.p. 30 min prior to implantation. This treatment inhibits the
increase in bladder weight and the onset of edema up to 9h post implantation compared to
saline treated controls (Fig. 27A) and causes similar degree of vascular permeability
relative to non-implanted animals at 6hpi (Fig. 16C). However, by 12h post implantation,
the bladders of dexamethasone-treated animals were as edematous and inflamed as
saline-treated implanted controls (Fig. 27B). Supplemental dosages of dexamethasone
administered 30 min prior to implantation and at 9h post implantation did not prevent
edema at 24h post implantation (data not shown). Interestingly, preliminary cytokine
profiling at 24h post implantation reveals that dexamethasone-treated and implanted
animals have significantly reduced G-CSF, KC, and interleukins 1β, 6, 12p40, and 17,
compared to saline-treated implanted controls (Fig. 28B). These soluble inflammatory
markers are upregulated at least two-fold in saline-treated implanted animals over nonimplanted

mock-infected

controls

following

urinary

implantation

(Fig.

28B).

Furthermore, dexamethasone-treatment significantly (p<0.05) reduced the infiltration of
monocytes, basophils and eosinophils in the bladder of implanted animals compared to
implanted controls at 24h post implantation (data not shown). Together, these data
indicate that activation of glucocorticoid-sensitive immune pathways contributes to the
onset of bladder wall edema, vascular permeability, pro-inflammatory cytokine
expression, and cellular recruitment following urinary implantation.
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The effects of dexamethasone treatment on enterococcal virulence in implanted animals
were assessed at 6h and 24hpi. As shown in Fig. 28A, enterococcal titers were ~1 log
significantly higher (p=0.0424) on implants recovered from dexamethasone-treated
animals compared to saline-treated implanted controls at 6hpi. No significant difference
in bacterial titers was observed in the bladder and kidneys between the two groups. By
24hpi, E. faecalis recovery from implants was similar in dexamethasone- and salinetreated animals (Fig. 28A). Interestingly, preliminary evidence indicate that enterococcal
infection in dexamethasone-treated animals restores the production of pro-inflammatory
markers, including IL-6, (Fig. 28B) and myeloid cell recruitment back to the levels
observed in saline-treated implanted controls (data not shown), suggesting that E. faecalis
infection induces a dexamethasone-independent immune response that is ineffective at
preventing and clearing E. faecalis from the urinary tract in the presence of a silicone
implant.
Implanted IL-6- and TLR-2-defective mice are susceptible to enterococcal infections
similar to their wild type littermates. Since IL6 is the most up-regulated proinflammatory cytokine in response to urinary implantation, its contribution to the
inflammatory response during E. faecalis infection was determined following OG1RF
inoculation of implanted IL6-deficient mice. E. faecalis is recovered from implants,
bladder, and kidneys of IL6-deficient animals at similar levels as their littermate wild
type controls (Fig. 29). Notably, preliminary data indicate that the absence of this
cytokine does not affect the overall inflammatory response at 24hpi as assessed by
cytokine profiling and flow cytometry analysis of wild type and IL-6-deficient animals
with or without implants in presence or absence of E. faecalis (data not shown).
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Together, although IL-6 is highly induced following urinary implantation, it is not a
critical mediator of the inflammatory response in implanted animals with or without E.
faecalis infections.

Figure 26: Dexamethasone treatment delays onset of bladder edema.
(A) Bladder weights of female C57Bl/6Ncr at the indicated time points treated with saline
or dexamethasone (10mg/kg, i.p.) 30 min prior to implantation. White bars from the same
dataset represent weight of non-implanted animals’ bladders. Experiment was done at least
twice with n=5/experiment/time point, except at 12 and 18h (experiment performed once).
Error bar = SEM. **p<0.005, ***p<0.005 by the Mann-Whitney U test. (B) H/E staining
of bladder sections obtained at the indicated time points from non-implanted and implanted
animals treated with saline or dexamethasone (10mg/kg, i.p.) observed under light
microscope at 40X magnification.
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Figure 27: Dexamethasone treatment enhances early enterococcal implant colonization.
(A) Graph represents OG1RF titers at 6 and 24hpi from retrieved implants, homogenized
bladders, and kidneys from saline or dexamethasone-treated implanted mice. The horizontal bars
indicate the median of each dataset from at least two independent experiments with n=510/condition/experiment. The horizontal dashed lines represent the limit of detection. (B) Graph
represents bladder cytokines with at least two fold differential expression relative to uninfected
non-implanted animals at 24 hpi of non-implanted and saline- or dexamethasone-treated
implanted animals with or without OG1RF from at least two independent experiments n=23/condition/experiment. Error bars = SEM. *p<0.05, **p<0.005 by the Mann Whitney U test.
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Given that myeloid cells, the primary responders to silicone implants, are critical for the
host pathogen recognition via expression of Toll-like receptors217 and TLR2 recognizes
lipoteichoic acid on the surface of Gram positive bacteria218, the contribution of TLR-2
was specifically assessed during E. faecalis infection. Implanted TLR-2-defective mice
are as susceptible to E. faecalis colonization as their wild type littermates (Fig. 29).
Preliminary confirmatory evidence was obtained from enterococcal infections of mice
deficient in the TLR adaptors MyD88 and TRIF, independently (data not shown).
Therefore, these findings suggest that the Toll-like receptor pathway is not critical in the
host immune recognition of E. faecalis, in agreement with the limited activation of
macrophages even in the presence of high levels of E. faecalis.

Figure 28: Defects in IL6 and TLR2 do not alter E. faecalis uropathogenesis.
Graph represents OG1RF titers at 6 and 24hpi from retrieved implants, homogenized bladders, and
kidneys of WT, TLR-2- and IL-6- deficient mice. The horizontal bars indicate the median of each
dataset from at least two independent experiments with n=5/condition/experiment. The horizontal
dashed lines represent the limit of detection.
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Neutrophil recruitment contributes to anti-enterococcal responses. Neutrophils are the
major immune cells recruited in response to E. faecalis infection in the urinary tract of
implanted animals (Fig. 18B). To assess the contribution of neutrophils to the
inflammatory response during E. faecalis infection, mice were rendered neutropenic
following anti-ly6G treatment219 administered i.p. 3 days and 1 day prior to implantation
and bacterial challenge. At 24hpi, there was an approximately 1 to 1.5 log increase in
CFU recovered from implants and organs of neutrophil-depleted animals compared to
isotype-control antibody-treated implanted animals (p<0.05 in all cases) (Fig. 30).
Together, these findings indicate that neutrophils are important for controlling
enterococcal colonization of the urinary tract during CAUTI.

Figure 29: Neutrophil depletion enhances enterococcal CAUTI.
Graph represents OG1RF titers at 24hpi on implants, in homogenized bladders and kidneys of
implanted isotype IgG control- (Isotype) and anti-Ly6G- (anti-PMNs) treated mice. The
horizontal bars indicate the median of each dataset from two independent experiments with
n=10/condition/experiment. The horizontal dashed lines represent the limit of detection for
implant and organs. *p<0.05, **p<0.005 value by the Mann Whitney U test.
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DISCUSSION
Enterococci, normally commensal bacteria of the human oral cavity and
gastrointestinal tract, have become important opportunistic pathogens in hospital settings.
While not historically regarded as an uropathogen in uncomplicated community acquired
cystitis, E. faecalis is now considered a major agent of hospital-acquired UTIs56 where
catheterization and indwelling medical devices can negatively impact patients’ defenses
against pathogens56. However, the lack of a robust animal model of enterococcal UTI has
impeded the study of this pathogen within the urinary tract. In previously established
models of ascending UTIs, E. faecalis fails to establish persistent bladder colonization
and primarily displays tropism to the kidneys before rapid clearance by the host105,187-191.
The absence of persistent infections in these murine models reflects the profile of E.
faecalis in community-acquired UTIs where this bacterium represents less than 5% of
clinical isolates220. As an opportunistic pathogen, E. faecalis requires alterations in
bladder homeostasis following urinary catheterization in order to achieve successful
infection of the urinary tract.
In this study, the pathophysiology of E. faecalis-mediated CAUTIs was
characterized using a murine model of foreign body-associated UTI modified from
previous studies29,194. In this murine model, E. faecalis colonizes and persists within the
urinary tract at very high titers. The striking difference in enterococcal bladder
colonization and virulence from previous models is a direct consequence of implantation,
which elicits major histological and immunological changes in the bladder similar to
those observed in spinal cord injured and post-surgical patients with indwelling urinary
catheters25-27,30. The importance of the bladder implant during E. faecalis uropathogenesis
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was made evident from the efficient bacterial clearance and the significantly lower titers
recovered from the urinary tract in the absence and/or with the loss of implants, even in
inflamed bladders following cyclophosphamide treatments. This is because the implant
provides an abiotic surface for enterococcal biofilm production within the bladder.

Figure 30: Model of enterococcal uropathogenesis in the context of urinary
catheterization.
The insertion and presence of a foreign body within the bladder induces an acute
inflammatory response involving edema, neutrophilia, and the production of proinflammatory cytokines and chemokines. This inflammatory response does not promote E.
faecalis infection. It is postulated that the failure of the host to block and disrupt enterococcal
biofilms produced on the surface of the foreign body leads to successful enterococcal
infections. Biofilm formation, involving the actions of SrtA and SrtC, as well as other known
and unknown biofilm determinants is critical for E. faecalis uropathogenesis.

Biofilms are central to the pathogenesis of chronic infections, including
CAUTIs38,40,112. Enterococcal biofilms on the surface of implants is essential for the
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establishment of persistent enterococcal urovirulence as demonstrated by virulence
attenuation of strains with mutations in genes encoding known and yet to be identified
biofilm determinants. Bacteria within biofilms, protected from the host immune
assaults49, may continuously seed the bladder preventing effective clearance by the host
and leading to persistent cystitis and pyelonephritis. It is important to note that not all
known in vitro biofilm-promoting or virulence factors are involved in E. faecalis
pathogenesis within the urinary tract as shown in the present study.

Specifically,

autolytic factors, such as GelE and Atn, are important mediators of DNA release during
biofilm growth in vitro103,104,121,127,210 and GelE a major virulence factor in animals
models of endocarditis221. Deletions of both atn and gelE do not alter enterococcal
biofilm formation on the implants nor virulence in the urinary tract. The ability of E.
faecalis to colonize the implants and establish persistent infections in the absence of both
Atn and GelE argues that extracellular DNA may not be an important contributor of the
extracellular matrix of enterococcal biofilms in vivo in the urinary tract or its release may
occur in an Atn/GelE-independent manner. Furthermore, the ability of the E. faecalis
gelE-defective OG1X strain to produce DNA-dependent biofilms in vitro, but yet unable
to colonize the implants and organs in the urinary tract, further supports the claim that
GelE is not a critical virulence factor for enterococcal uropathogenesis. However, since
OG1X was derived from chemical mutagenesis209, it is likely that additional mutations
that may compensate for the loss of GelE production during DNA-dependent biofilms
and/or are necessary for E. faecalis uropathogenesis in vivo. Consistent with these
findings was the observation that gelatinase is not expressed in 71/163 clinical isolates172
of E. faecalis and the presence of gelE does not correlate with gelatinase expression192 or
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their ability to produce biofilms in vitro172. However, a recent study by Arciola et al
found a correlation with a high GelE phenotype and the ability to form biofilms from
orthopedic implant infections222, indicating that the factors utilized by enterococci in
forming biofilms may depend on substrate and/or site of infection. Identification of the
major components of the extracellular matrix of in vivo enterococcal biofilms and the
single nucleotide polymorphisms (SNPs) between OG1RF and OG1X will lead to a better
understanding of enterococcal CAUTIs and will be of valuable interest for designing
therapeutics that promote the prevention and disruption of these structures.
While GelE and Atn are dispensable for E. faecalis pathogenesis, the enterococcal
enhanced expression of pheromone (Eep) metalloprotease, the transcriptional regulator
AhrC, and the enterococcal sortases are important mediators of full virulence in
implanted animals. In particular, sortases A and C are well-established biofilm-promoting
factors in E. faecalis106,109,210.

Recent studies have shown that sortases, which are

transpeptidases that anchor LPXTG-containing surface proteins to the cell wall of Grampositive bacteria143, plays important roles in in vitro biofilm development106,109,210.
Deletions of both srtA and srtC in E. faecalis prevent adherence and subsequent biofilm
growth on abiotic surfaces210. Although Kemp et al reported that disruption of srtA,
unlike srtC, did not significantly affect virulence in a murine model of ascending UTI106,
results from the murine model of enterococcal CAUTI reveal that SrtA contributes to E.
faecalis virulence in the urinary tract. The srtA-deficient mutant is unable to colonize the
implants in vivo and is significantly attenuated in CAUTI. Similar results were obtained
following infection of implanted animals with a srtC-deficient mutant. These findings
further underscore the importance of biofilm production during E. faecalis pathogenesis
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and strongly suggest that SrtA-dependent substrates and the enterococcal endocarditisand biofilm associated pili (ebp) found in most clinical isolates of E. faecalis and several
E. faecium strains167,223 are involved in attachment to abiotic surfaces and/or to abraded
uroepithelium in vivo during the establishment of CAUTI. Evidence obtained in
collaboration with Hailyn V. Nielsen at Washington University in St. Louis who
generated a deletion mutant of the ebp operon in OG1RF demonstrates a function for Ebp
in virulence during CAUTI (Nielsen, H.V., Guiton, P.S., et al, manuscript in preparation),
in agreement with previous reports that mutations in this operon significantly reduces
biofilm formation and attenuates virulence in a murine model of ascending UTIs in E.
faecalis and E. faecium107,145,167,223. It will be of particular interest to understand the
molecular mechanisms underlying the role of Epb during CAUTI and identify additional
SrtA-dependent substrates116 critical for urovirulence as they represent attractive targets
for drug development given their ubiquitous nature and important functions in virulence
116,164

. For example, recently characterized LPxTG motif-containing proteins, EF3314

and SrgA, contribute to enterococcal biofilm formation169,224. EF3314 is also involved in
E. faecalis adherence to host cells and survival within macrophages and Caenorhabditis
elegans169. Furthermore, surface proteins known as microbial surface components
recognizing adhesive matrix molecules (MSCRAMMs), which include putative SrtA
substrates, have been identified in E. faecium and E. faecalis225-227. MSCRAMMs, such
as enterococcal collagen-binding adhesin ace165,228 or the SagA-like SalA and SalB
proteins229, can bind to host cells via interactions with extracellular matrix components
like collagen and fibrinogen. Several proteins from this family have been implicated in
enterococcal virulence properties, biofilm formation, endocarditis and UTIs91,167,230,231.
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The disruption of urothelial surfaces, as a result of urinary catheterization, may expose
receptors that SrtA-dependent cell surface proteins, such as MSCRAMMs, can recognize
to promote attachment, biofilm formation and persistent colonization.
Additionally, the findings in this report helps unravel critical aspects of the
interplay between inflammation and enterococcal colonization, providing new details of
the molecular mechanisms leading to implant-mediated inflammatory response and its
role on the outcome of E. faecalis infection. The bladder responses to urinary
catheterization are characterized by severe uroepithelial damage, the onset of bladder
wall edema from increased vascular permeability, and upregulation of inducible nitric
oxide synthase (preliminary data not shown). The presence of the implant stimulates the
production of pro-inflammatory cytokines, including IL-6 and KC (IL-8 or CXCL1)
previously shown to be induced following catheter-mediated abrasions of bladder
epithelial cells in vitro232, and G-CSF. In contrast, GM-CSF and MIP-1α (CCL3)
expression was decreased following implantation. The presence of E. faecalis in
implanted animals, albeit at very high titers, slightly enhances the inflammatory response
with a specific increase in the production of IL-1β, GM-CSF and MIP-1α (the latter back
to non-implanted, uninfected control levels) during CAUTI. These cytokines are
produced by epithelial cells, neutrophils and other immune cells and are important
mediators of the inflammatory response to mucosal injuries and microbial infections233238

. In particular, IL-1β was shown to be released during UPEC-mediated acute cystitis239.

This cytokine profile of implanted bladders is in agreement with the identity of the
myeloid cell infiltrates primarily in response to urinary implantation. Neutrophils, whose
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presence is doubled in E. faecalis infected implanted animals, are the primary responders
followed by monocytes, macrophages, basophils, and some eosinophils.
All the above immune characteristics, from edema to neutrophilia, are associated
with activation of the neurogenic inflammatory pathway in various experimental models
of cystitis, including cyclophosphamide-induced hemorrhagic cystitis214.

This is an

inflammatory response triggered by the release of proinflammatory neuropeptides and
activation of surface receptors, including NK1R, on the surface of sensory neurons197.
However, NK1R and α1-adrenoreceptor-mediated neurogenic inflammatory responses
are not major contributors of implant-induced cystitis in mice since treatment with
specific NK1R antagonists and α1-adrenoreceptor as well as iNOS inhibitors did not
prevent plasma protein leakage and edema as was previously shown in bladder cystitis or
other experimental models involving activation of the neurogenic pathway204,206,240. This
is further supported by preliminary evidence from implantation of cKit-deficient mutant
mice revealing that mast cells, important cellular components of the neurogenic
pathway198,241,242, are not major inducers of edema and vascular permeability following
urinary implantation (data not shown). Although the contribution of other factors
involved in the neurogenic inflammatory response, including bradykinins and NK2
receptors, need to be assessed, identifying the effects of urinary implantation on factors
involved in vascular permeability, such as calcium channels, calveolin, RhoGTPases,
sphingosine kinases (SPHK1) and protein tyrosine phosphatases (SHP2)243, may shed
light into the mechanisms underlying the onset of bladder wall edema following
catheterization.
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In contrast to studies with inhibitors of the neurogenic inflammatory response,
glucocorticoid treatment delays the onset of implant-associated edema and partially
decreases cytokine production and cellular recruitment following urinary catheterization,
thus implicating glucocorticoid-responsive inflammatory pathways in the immune
response during the early stages of urinary implantation. Synthetic glucocorticoids such
as dexamethasone are the most effective anti-inflammatory agents used to date for the
treatment of chronic inflammatory diseases244. They are both anti-inflammatory and
immunosuppressive molecules whose mechanisms of action involve in part
transcriptional regulation via interaction and activation of glucocorticoid receptors (GR)
in the host cytoplasm as well as post transcriptional and translational regulation of a
myriad of genes encoding proteins for cellular and immune processes244,245.
Glucocorticoids are known inhibitors of inflammatory processes mediated by interleukins
(1β, 2, 6, and 8) and other pro-inflammatory cytokines such as (GM-CSF and TNF-α),
cyclo-oxygenases

(particularly

COX-2),

and

iNOS.

The

unresponsiveness

to

dexamethasone observed in the later stages of urinary implantation has previously been
reported in patients suffering from other inflammatory diseases246, including asthma247,
inclusion body myositis (IBM)248, and nephrotic syndrome (NS) in children249. In the
case of the implanted bladders, glucocorticoid refractoriness could be attributed to the
ongoing exposure to the foreign body250, the high levels of neutrophils in the bladder
which have been previously associated with corticosteroid-resistant asthma250, a
significant reduction in glucorticoid receptors251 due to increased urothelial exfoliation,
or other cellular and immunological pathways that can circumvent the effects of
dexamethasone250. These may include an increased expression of the dominant negative
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form of the glucorticoid receptors (GRβ) on immune cells such as neutrophils and
macrophages rendering them insensitive to dexamethasone treatment252,253, upregulation
of certain cytokines including IL-2, IL-4, and IL-13, or from activation of the mitogenactivated protein kinase (MAPK) signaling pathways250. Notably, the suppression of the
early phase of implant-mediated cystitis following glucocorticoid treatment or iNOS
inhibition (data not shown) led to a significant increase in enterococcal implant
colonization. Remarkably, enterococcal infection in dexamethasone-treated animals
induces an immune response similar to that elicited by the implants in uninfected salinetreated controls. These findings suggest that E. faecalis possesses immune evasion
mechanisms that allow its survival in the face of this glucocorticoid-resistant immune
response and that implant-mediated bladder inflammation as in the case of pre-implanted
animals did not alter the outcome of infection. The acute inflammatory response induced
by the implant may even alter or impair the host response to bacteria, as was
demonstrated for E. faecium peritonitis following treatment with turpentine or casein
prior to bacterial challenge254.
E. faecalis colonization is also significantly increased in the bladders of
neutropenic mice following urinary implantation, corroborating previous reports of that
neutrophils are important mediators of the anti-enterococcal host response in humans and
other animal models of infections236,255-257. Previous studies demonstrated that E. faecalis
and E. faecium isolated from saliva and root canals are efficiently killed by neutrophils
recruited to the site of infection258 and that TLR-2 is involved in the immune response
against E. faecium259. However, the immune functions of neutrophils during E. faecalis
infections of the urinary tract occur in a TLR-2 and IL-6 independent manner as infection
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of implanted animals deficient in these immune modulators did not alter the outcome of
infection. Further research is required to establish the contribution of macrophages and
other immune cells, the toll like receptors, IL8, and G-CSF signaling pathways in the host
immune response to enterococcal CAUTI.
Despite the role of neutrophils in controlling E. faecalis infection, this bacterium
is still able to colonize the urinary tract of implanted immunocompetent mice, implying
the presence of potential mechanisms to help E. faecalis avoid and/or resistant neutrophil
killing. Recent studies have demonstrated that the cell wall anchored pheromoneinducible aggregation substance (AS) and the enterococcal polysaccharide antigen (Epa)
in E. faecalis are involved in resistance to neutrophil-mediated killing260-262. However,
the E. faecalis OG1RF strain used in the present study does not bear AS, arguing for
alternative mechanisms of immune evasion, such as the downregulation of integrin 4
expression of the surface of neutrophils263, alteration of the neutrophil properties
rendering them non responsive to bacterial infections as is the case during enterococcal
sepsis in thermally injured patients and mice236,256,257 or survival within immune cells
such as macrophages which is a well characterized virulence attribute of enterococci
186,264-271

. Together, these findings indicate that the inflammatory response to the urinary

implant can be deleterious to E. faecalis, but is inefficient at controlling bacterial
proliferation and colonization over time. Furthermore, this report is in accord with
epidemiological reports of severe enterococcal infections increasingly occurring in
immunosuppressed and immunocompromised patients272-275.
In addition to promoting persistent enterococcal cystitis, the presence of the
silicone implants in the bladder allows E. faecalis to gradually and successfully ascend to
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the kidneys and establish renal colonization in implanted animals. The onset of acute
pyelonephritis has been described in post-mortem studies of the elderly with indwelling
catheters at the time of death276. In the clinical setting, the removal of infected indwelling
urinary catheters is one of the most effective methods used to resolve bacteriuria and
CAUTIs34,40. However, removing the indwelling medical device, even combined with
long course of antibiotics treatment40, may not be sufficient for complete resolution of the
infection, especially with the rise in antibiotic resistance observed in nosocomial
settings277. In addition, implant removal upon infection in other device-associated
infections like prosthetic valve endocarditis is not in itself efficacious278-280, and thus may
not be a suitable therapeutic approach in all instances. Understanding the pathogenesis of
CAUTIs may lead to new and better ways to treat and prevent these diseases.
The optimized murine model of foreign-body associated UTI presented here is
highly relevant for the investigation of the mechanisms underlying enterococcal-mediated
CAUTIs since it couples biofilm production to enterococcal virulence during E. faecalis
uropathogenesis. Findings from this study in this murine model led to the conclusion that
the acute inflammatory response induced by urinary catheterization, partially responsive
to glucocorticoid treatment, does not promote enterococcal infection rather the
establishment of successful infections by this opportunistic pathogen results from the
failure of the immune response, especially neutrophils, to prevent, block, or disrupt
biofilm formation, rendering this process a major target in the fight against enterococcal
CAUTIs (Fig. 31). This murine model represents a valuable and robust tool for
understanding the mechanisms underlying urinary catheter-mediated cystitis and for the
identification and characterization of novel biofilm determinants, bacterial virulence
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factors as well as host responses pertinent to the pathogenesis of E. faecalis in the urinary
tract. Importantly, it will serve as an ideal platform for testing anti-biofilm compounds
and potential therapeutics for the prevention and treatment of enterococcal CAUTIs.
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CHAPTER THREE
CONSEQUENCES OF URINARY CATHETERIZATION ON
UROPATHOGENIC ESCHERICHIA COLI PATHOGENESIS
Modified from: Guiton, P.S., et al. manuscript submitted.
ABSTRACT
Catheter-associated urinary tract infections (CAUTIs) caused by multidrug
resistant pathogens including uropathogenic Escherichia coli (UPEC) constitute the
majority of nosocomial UTIs and pose significant clinical challenges. Urinary
catheterization elicits major histological and immunological alterations in the bladder that
can favor microbial colonization and dissemination in the urinary tract. The present study
reports the consequences of these biological perturbations on uropathogenic Escherichia
coli (UPEC) pathogenesis and virulence-based preventative measures using an optimized
murine model of foreign body-associated urinary tract infection (UTI). The findings
obtained demonstrate that type 1 pili mediate UPEC adherence and invasion into bladder
epithelial cells in catheterized bladders as seen in non-catheterized bladders as well as to
the urinary implant. Specific targeting of type 1 pili with small molecule inhibitors in
combination with trimethoprim/sulfamethoxazole prevents UPEC CAUTI. This study
further demonstrates that bacterial reservoirs established during previous UPEC infection
can serve as a nidus for urinary catheter colonization. This study provides novel insight
into UPEC pathogenesis in the context of urinary catheterization, and investigates novel
therapies that target critical mechanisms for this pathophysiology. By doing so, it
establishes a proof-of-principle for the development of novel therapies to prevent and
eventually treat these infections in the face of the rise of antibiotic resistant uropathogens.
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INTRODUCTION
CAUTIs often arise from multidrug resistant Gram-positive and Gram-negative
bacterial colonization and biofilm aggregation on the surface of indwelling urologic
devices such as urinary catheters, rendering treatment very difficult33,40,56. Uropathogenic
Escherichia coli (UPEC), the primary cause of community-acquired UTI, account for
50% of nosocomial UTIs, including CAUTIs55. Yet, very little is known about its
pathogenesis following urinary catheterization. Urinary catheterization results in the
disruption of the normal mechanical and antimicrobial defenses of the bladder25,26,29,30,281.
Previous reports using human biopsies and rodent models of infections have shown that
the catheterized bladder is edematous and highly inflamed with immune cell infiltration
and pro-inflammatory cytokine production, an environment quite different from that
which UPEC encounters in a non-catheterized bladder62,71-73,75,77,282 . We hypothesized
that these profound catheter-related changes may affect UPEC pathogenesis.
The UPEC pathogenic cascade has been extensively characterized in a noncatheterized murine model of cystitis. UPEC elaborate on their surface adhesive type 1
pili, which mediate binding to and invasion of superficial umbrella cells lining the
bladder epithelium60. Once intracellular UPEC can escape into the cytoplasm, replicate
rapidly and undergo morphological differentiation within bladder epithelial cells to
produce mature intracellular bacterial communities (IBCs) of ~104-105 bacteria with
biofilm-like properties73,74. UPEC then flux out from infected cells and can reinvade
neighboring cells and start the process de novo73. This acute phase of UPEC infection can
lead to the development of chronic cystitis, pyelonephritis, and the formation of quiescent
intracellular reservoirs (QIRs) with absence of bacteriuria77. Detailed understanding of
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the critical steps of this pathogenic cascade has led to the development of small molecule
inhibitors called mannosides84. Mannosides specifically target the bacterial type 1 pili tip
adhesin, FimH, which binds to mannosylated residues present on the surface of the
bladder epithelium. Rationally designed to interfere and prevent FimH interaction with
these residues, mannosides inhibit UPEC binding and invasion of the superficial umbrella
cells during urinary tract infections (UTIs)84. Mannosides, in combination with existing
antibiotic-based UTI therapy, have recently been shown to be effective in preventing and
treating UPEC infections in non-catheterized infection models87. The present study
investigates whether this therapeutic approach could be beneficial in the prevention and
treatment of CAUTIs.
In this report, the optimized murine model of foreign body-associated UTI that
closely mimics CAUTI29 was used to investigate the consequences of urinary
catheterization on the pathophysiology of UPEC infection. For these studies, several
UPEC virulence parameters, including the contribution of type 1 pili, IBC formation, and
QIR reactivation, were assessed. The results obtained indicate that urinary catheterization
provides UPEC with the opportunity to exploit the extracellular milieu of the bladder via
type 1 pili-mediated biofilm formation on the surface of the foreign body, which results
in a shift in the niche population. Administration of mannosides in combination with
trimethoprim/sulfamethoxazole prior to urinary catheterization prevents UPEC
colonization of the urinary tract. This report provides important insights into the
mechanisms underlying UPEC-mediated CAUTI, and informs efforts to design better
therapeutic approaches to prevent and potentially treat these infections.
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RESULTS
UPEC adherence, invasion, and IBC morphology are unaltered in catheterized
bladders.
To assess the effects of urinary catheterization on UPEC colonization patterns in
the urinary tract, 4-5mm platinum-cured silicone tubing sections (referred to as implants)
were implanted in the bladders of C57Bl/6Ncr female mice, which were then
immediately infected with 1-2x107 CFU of the well-studied virulent UPEC strain
UTI89282 by transurethral catheterization. CFU enumeration was compared to nonimplanted animals similarly infected with UTI89 up to 7 days post infection. UPEC
colonized the bladder and kidneys of implanted animals to similar levels as in nonimplanted animals (Fig. 32). In addition to the organs, UPEC was also recovered at very
high titers from the implants, on which they established biofilms as determined by
scanning electron microscopy at 48hpi (data not shown).
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Figure 31: Bladder implantation does not alter the overall colonization pattern of UPEC.
Graphs represent bacterial titers in log scale from retrieved implants (A), homogenized bladders
(B), and kidneys (C) from non-implanted (○) or implanted (●) animals infected with 1-2x107
CFU in 50µl inoculum of E. coli strain UTI89 for 24, 48, 72 hpi, or 7 dpi. Horizontal dashed
lines represent the limit of detection for viable bacteria. Each symbol represents a mouse from
two independent experiments with n=5/condition. The horizontal bars represent the median of
each dataset; *p<0.05, **p<0.005, and ***p<0.0005 by the Mann Whitney U test.

IBC formation occurs in the pathogenesis of UPEC in non-catheterized patients78 and has
been shown in mouse models to be critical for infection. To assess the effects of urinary
catheterization on IBC formation, implanted and non-implanted mice were infected with
UTI89 as described above. Ex vivo gentamicin protection assays62 performed at 3hpi
revealed no statistical difference in either the extracellular or intracellular UPEC
populations in the presence or absence of implants (Fig. 33), indicating no gross defect in
bacterial invasion in implanted animals. IBC formation within both implanted and nonimplanted bladders was assessed by LacZ staining and confocal scanning laser
microscopy (CSLM) at 6hpi (Fig. 34A-C). Inoculation of UPEC into implanted animals
resulted in significantly fewer IBCs with a median of 8 IBCs/bladder (p=0.0044) (Fig.
34B) compared to non-implanted animals in which IBC numbers ranged up to >250
IBCs/bladder with a median of 55 IBCs/bladder. Yet, bacterial CFU in implanted
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bladders were similar to those in non-implanted animals (data not shown). This
observation led to the reasoning that IBC morphology might be different in implanted
animals. However, IBCs formed in implanted animals were observed to be overall similar
in size and shape as those produced in non-implanted bladders (Fig. 34C). UPEC were
also seen to produce multiple IBCs within one umbrella cell and filamentous bacterial
clumps in both catheter implanted and non-implanted bladders at 6hpi (Fig. 35). UPEC
colonization at 6hpi was selectively localized in the remaining umbrella cells and not
observed in the exposed underlying epithelium in implanted bladders (Fig. 35). Together,
these findings indicate that urinary catheterization negatively impacts IBC formation by
UPEC, possibly due to a correlated increase in exfoliation of the superficial umbrella
cells283.
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Figure 32: No defect in UTI89 invasion following implantation.
Graph represents bacterial titers from homogenized bladders from non-implanted (○) or implanted
(●) animals infected with UTI89 3hpi following ex vivo gentamicin protection assay. Horizontal
dashed lines represent the limit of detection for viable bacteria (Int=intracellular, Ext=Extracellular).
Each symbol represents a mouse from two independent experiments with n=5/condition. The
horizontal bars represent the median of each dataset; p value by the Mann Whitney U test.
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Figure 33: Uropathogenic E. coli produces IBCs in the superficial umbrella cells of
implanted bladders.
(A) Representative images of splayed bladders of female C57Bl/6Ncr mice infected with UTI89
6hpi in the absence (non-implanted) or presence (Implanted) of implants following LacZ staining.
Each black arrow indicates a purple speck, indicative of an IBC. (B) Quantification of IBC
formation following LacZ staining at 6hpi. Each symbol represents IBC number from a single
mouse from two independent experiments with n=5/group. p value obtained from the Mann
Whitney U test. (C) Representative CLSM images of whole bladders from non-implanted and
implanted animals infected with UTI89 ectopically expressing GFP (Green), stained with DNA
dye SYTO83 (Red) and Alexa-fluor 633-conjugate of WGA (Blue) reveal the presence of IBC
within umbrella cells. Scale bar =20µm.
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Figure 34: IBC and filamentation occur following urinary catheterization
Representative CLSM images of whole bladders from non-implanted and implanted animals
infected with UTI89 ectopically expressing GFP (Green), stained with DNA dye SYTO83 (Red)
and Alexa-fluor 633-conjugate of WGA (Blue) reveal the presence of multiple IBCs within single
umbrella cells (A-B), that unlike non-implanted bladders (C), the underlying epithelium is
exposed following urinary catheterization (D-F), depict the absence of bacterial colonization of
the exposed underlying epithelium in implanted animals (D-F), and the presence of filamenting
bacteria in umbrella cells (E-F). Scale bar =20µm.

Bacteria originating from bacterial reservoirs can seed urinary implant
colonization.
One troubling possible outcome of the UPEC pathogenic cascade is the
establishment of quiescent intracellular reservoirs (QIRs) in the underlying epithelial
layers, which have been shown, can be a source of recurrent UTIs (rUTIs)77,284. QIRs
were shown to be reactivated following treatment with protamine sulfate, a chemical that
leads to exfoliation of the superficial umbrella cells of the uroepithelium

77

. Like

protamine sulfate, urinary catheterization causes severe damage to the protective
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uroepithelial layer77. Thus, urinary catheterization might also reactivate QIRs, resulting in
bacteriuria, catheter colonization and further dissemination. To test this hypothesis, mice
were infected with 1-2x107 CFU UTI89HK::GFP and infection allowed to resolve over
the course of 2 weeks. On day 14 post-infection, urine was collected from each animal to
assess infection state prior to urinary implantation of a subset of these animals. Those
animals in which titering of urines 14 dpi indicated bacteriuria (≥104 CFU/ml) were
considered to have active (non-resolved and/or recurrent) infection and were removed
from further analysis. The remaining mice were presumed to either have completely
cleared the infection or to have established QIRs. 3 or 5 days post implantation,
reservoirs activation was assessed by bacterial colonization of implants and bladder. On
day 3 post implantation, UPEC UTI89HK::GFP was recovered from implants in 3 of 26
implanted mice (~11.5%) and one mouse had bladder colonization (> 104 CFU) compared
to none of 22 similarly infected but non-implanted animals (Fig. 36A). For mice assessed
at 5 days post-implantation, UTI89HK::GFP was recovered from implants of 4 out 32
animals (~13%) with two of them having bladder titers greater than 104 CFU/ml (Fig.
36B) compared to 0 out of 23 in non-implanted animals. Interestingly, there were overall
significantly fewer bacteria recovered from the bladders of implanted animals compared
to non-implanted animals at 5 dpi (p=0.017; Fig. 37B), suggesting that either reactivated
reservoirs are cleared by the immune response prior to day 5 following implantation or
increased exfoliation prevents establishment of persistent infections. Together, these data
indicate that urinary catheter colonization can occur from previous urinary infections
even if those infections appear by bacteriuria counts to have been resolved.
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Figure 35: Bacterial reservoir reactivation can lead to implant and bladder colonization.
Graphs represent bacterial titers in log scale recovered from implants, homogenized bladders and
kidneys of non-bacteriuric animals 14days post infection with UTI89HK::GFP that were nonimplanted or implanted for 3 day (A) or 5days (B). Horizontal dashed lines represent the limit of
detection for viable bacteria. Each symbol represents a mouse from at least two independent
experiments with n=10-20/group/experiment. The horizontal bars represent the median of each
dataset; p value by the Mann Whitney U test.
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FimH is required for biofilm formation and UPEC colonization of the urinary tract
following catheter implantation.
Biofilm formation is a critical component of UPEC CAUTI pathophysiology33,37.
Type 1 pili are major UPEC virulence factors that have been shown to be critical for
biofilm aggregation, IBC formation, and other aspects of UPEC uropathogenesis. Thus,
the contribution of these extracellular pili as well as other UPEC fibers, including curli
which contribute to biofilm formation285 or S pili associated with E. coli clinical isolates
producing strong biofilms286-288, to biofilm formation in filtered human urine under flow
conditions and UPEC-mediated CAUTI in vivo. Deletion of the gene for the tip adhesin
of type 1 pili, fimH, in UTI89 resulted in significantly (p<0.0001) lower biomass (Fig.
37A) and an approximate 2-fold reduction in adherent viable bacteria (Fig. 37B) in
biofilms formed in human urine in vitro. These data indicate that type 1 pili are a major
contributor to UPEC biofilm formation in urine. The biofilm defect was specifically
associated with the fimH mutant under these conditions, and was not observed following
deletions of the sfa operon to prevent S pili formation, csgA required for curli fiber
formation, or a component of the flagellar system fliC (data not shown).
In vivo, similar to findings in a murine model of cystitis, UTI89∆fimH is severely
attenuated in the murine model of foreign body-associated UTI (Fig. 37C). UTI89∆fimH
displayed >3 log fewer CFU in the bladder and was unable to ascend to the kidneys at
24hpi. Further, deletion of fimH resulted in significant reduction in implant colonization
(p<0.0001).
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Figure 36: Deletion of fimH reduces biofilm formation and attenuates UPEC virulence.
Graphs represent crystal violet based quantification (A) and CFU enumeration in logarithmic
scale (log scale) (B) of 24h old UTI89 and UTI89∆fimH (∆fimH) biofilms under human urine
flow on silicone tubing at 37ºC indicating that ∆fimH is defective in biofilm formation under
these conditions. Bars represent mean of three independent experiments, error bars indicate
standard error of the mean (SEM). p values from Mann Whitney U test. (C) Graph represents
bacterial titers in log scale recovered from implants, homogenized bladders and kidneys of nonimplanted (open symbols) and implanted (closed symbols) infected with either UTI89 (square) or
∆fimH (circle) for 24h.

Horizontal dashed lines represent the limit of detection for viable

bacteria. Each symbol represents a mouse from at least two independent experiments with
n=5/group. The horizontal bars represent the median of each dataset; *p<0.05 and ***p<0.0005
by the Mann Whitney U test.
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Similar to in vitro experiments, S-pili are not required for CAUTI since UTI89∆sfaA-H is
as virulent as wild type UTI89 and a double deletion of both sfaA-H and fimB-H
recapitulated the UTI89∆fimH phenotype (Fig. 38A). Furthermore, components of the
curli system important for biofilm formation in vitro under certain conditions, but not in
human urine (Fig. 3A-B), were also dispensable during CAUTI (Fig. 38B). The residual
binding to implants and bladders in implanted animals could therefore be attributed to
other pili or biofilm determinants. Together, these data strongly suggest that the tip
adhesin FimH of type I pili is a critical determinant of UPEC virulence in mediating
biofilm formation and virulence during CAUTI.
Mannoside treatment reduces IBC formation.
Having established that FimH is required for UPEC virulence in implanted
bladders, this adhesion was investigated as a potential therapeutic target for CAUTI using
small molecules inhibitors designed to interfere with FimH binding to mannosylated
residues84. This family of small molecules, called mannosides, has recently been shown
to prevent acute and chronic UPEC infections and potentiated the effectiveness of
antibiotics in combinatorial treatment87. To investigate the potential therapeutic effects of
mannosides on CAUTI, the inhibitory effects of methyl-α-D-mannopyranoside (methyl
mannose) on UTI89 biofilm formation in urine under flow was determined. Similar to the
deletion of fimH (Fig. 37A-B), UTI89 biofilms grown in presence of 1% methyl mannose
had significantly reduced biomass (p=0.0022) and biofilm-adherent cells (p=0.0012),
compared to untreated controls (Fig. 39). Since methyl mannose is a FimH antagonist,
these data confirm the critical role of type 1 pili to biofilm formation in urine as was
previously described for biofilms formed in LB media.
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Figure 37: S pili and curli are not critical for UPEC virulence following urinary
catheterization.
Graphs represent bacterial titers in log scale recovered at 24hpi from implants, homogenized
bladders and kidneys of (A) implanted animals infected with either UTI89 (●) or UTI89 mutant
strains deficient in type 1 pili, ∆fimH (■), S pili ∆sfaA-H(▲), both type 1 and S pili ∆sfaAH∆fimB-H(♦) and (B) non-implanted (open symbols) or implanted (closed symbols) animals
infected with UTI89 (○,●), ∆fimH (□, ■) or UTI89 mutant strains deficient in curli components
∆csgA (∆,▲) and ∆csgB∆csgG (♦,◊). Horizontal dashed lines represent the limit of detection for
viable bacteria. Each symbol represents a mouse from at least two independent experiments with
n=5/group. The horizontal bars represent the median of each dataset; *p<0.05 and ***p<0.005
**p<0.0005 by the Mann Whitney U test.

The effects of mannoside treatment were then assessed in vivo by using IBC
formation as well as implant and urinary tract colonization as benchmarks of disease
progression. Mice were treated intraperitoneally (i.p.) with saline or 5mg/kg of
mannoside ZH5684 in PBS 30min prior to urinary implantation. Mannosides, including
ZH56, are more potent than methyl mannose in preventing and disrupting UTI89 biofilm
in vitro. Methyl mannose, previously shown to inhibit UTI89 biofilm at 100mM in LB
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using the 96-well biofilm assay289 was used for the in vitro urine catheter biofilm studies
while the more potent mannoside was reserved for the in vivo studies due to its increased
affinity and stability. Catheter implantation was immediately followed by transurethral
inoculation of UTI89. IBC formation and bacterial colonization were assayed by LacZ
staining and CFU enumeration of implants, bladders, and kidneys at 6hpi and 24hpi,
respectively. As shown in Fig. 40A and 40B, mannoside treatment further reduced IBC
formation (p=0.0051) and bladder colonization (p=0.0114) in implanted animals at 6hpi,
suggesting that this treatment prevents intracellular infection. While eliminated from
their intracellular niche, data further indicated that UPEC were able to persist in the
extracellular milieu where they can colonize the surface of the implants to relatively
similar levels as saline-treated animals (p=0.0547) (Fig. 40B). No statistical difference
was observed in kidney colonization in the presence or absence of mannosides (Fig.
40B). By 24hpi, a time point at which the mannosides have been eliminated from the
bladder87, similar bacterial loads were recovered from implants, bladders, and kidneys in
implanted animals in the presence or absence of mannoside treatment (data not shown).
Furthermore, treatment with mannosides did not have an effect on established UPEC
CAUTI (data not shown).
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Figure 38: Methyl mannose inhibits UPEC biofilm in human urine
Graphs represent crystal violet based quantification (A) and CFU enumeration in logarithmic
scale (log scale) (B) of 24h old UTI89 biofilms in human urine with or without 1% methyl
mannose under flow on silicone tubing at 37ºC indicating that methyl mannose prevents UPEC
biofilm formation. Bars represent mean of three independent experiments, error bars indicate
standard error of the mean (SEM). p values from Mann Whitney U test.

Mannoside treatment increases the efficiency of TMP-SMZ in preventing UPEC
colonization.
In order to examine whether mannosides could prevent establishment of CAUTI
when used in combination with antibiotics, animals were treated with 54 and 270µg/ml of
trimethoprim-sulfamethoxazole (TMP-SMZ), respectively, in their drinking water for 3
days and then treated with saline or mannoside (5mg/kg) i.p. 30 min prior to implantation
and bacterial inoculation. At 6hpi, UPEC colonized the implants and bladders at
significantly lower levels in animals that only received antibiotics compared to those who
received water or were only administered mannoside (Fig. 40B). Interestingly, mannoside
treatment in addition to TMP-SMZ further decreased UPEC colonization of implants,
bladders, and kidneys compared to treatment with antibiotic alone (p<0.0005 in all
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cases). Together, these findings indicate that virulence-targeted therapies in combination
with established antibiotic treatment can help prevent or delay the onset of CAUTI.
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Figure 39: Mannoside treatment prevents IBC formation and UPEC virulence when use in
combination with TMP-SMZ. (A) Graph represents IBC enumeration from LacZ staining of
splayed bladders of female C57Bl/6Ncr mice treated i.p. with mannoside or saline prior to
transurethral implantation and inoculation with UTI89 6hpi. (B) Graph represents bacterial titers
in log scale recovered at 6hpi from implants, homogenized bladders and kidneys of animals
treated with saline (○), mannoside (□),TMP-SMZ (●) and TMP-SMZ+Mannoside (■) prior to
urinary implantation and inoculation with UTI89. Horizontal dashed lines represent the limit of
detection for viable bacteria. Each symbol represents IBC number or bacterial titer from a single
mouse from two independent experiments with n=5/group. The horizontal bars represent the
median of each dataset; *p<0.05, **p<0.0005, ***p<0.0005, ns corresponds to p>0.05 by the
Mann Whitney U test.
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DISCUSSION
UPEC is the major etiological agents of CAUTI56. Yet, the molecular mechanisms
of urinary catheter and bladder colonization following urinary catheterization have not
been elucidated. Studies in an optimized murine model of foreign body-associated UTI281
show that urinary catheterization favors UPEC exploitation of the bladder extracellular
milieu. This occurs via type 1 pili-dependent biofilm formation on the surface of silicone
implants in the murine bladder. The data further indicate that of the biofilm determinants
tested, type 1 pili are necessary for implant, bladder, and kidney colonization during
CAUTI; providing definitive experimental evidence for previous reports postulating that
type 1 pili may be required for UPEC persistence during CAUTIs290. Interestingly, fimHdeficient UPEC strains have the ability to adhere to some extent to the surface of the
foreign body, probably using other biofilm determinants such as other chaperone-usher
pili systems, curli, or surface adhesins43.
In addition to colonizing the foreign body in the bladder lumen, UPEC is able to
exploit intracellular niches in implanted animals, albeit to a lesser degree than in nonimplanted animals, by invading and producing IBCs in the early stages of infection.
Reduced IBC formation in implanted animals may be a result of loss of the host
superficial facet cells in which IBCs form due to increased exfoliation or damage to the
uroepithelium following urinary catheterization25,26,29,30,281,283,291. Nonetheless, this
finding is of particular interest for treatment strategies against UPEC-mediated CAUTI.
In humans, removal of the contaminated urinary catheter is the preferred method for
treatment of these infections34,40; however, the presence of bacteria in an intracellular
compartment protected from host immune defenses and antibiotic treatment requires
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more comprehensive approaches as intracellular UPEC can lead to re-infection of a novel
catheter or serve as a nidus for future UTI.
Quiescent intracellular reservoirs are an important outcome of UPEC pathogenic
cascade because they are proposed to be a mechanism of recurrent UTI following damage
to the uroepithelium77. Findings from the current study indicate that urinary implantation
of animals with a history of UTI can lead to bladder infection and implant colonization
with the UPEC causing the first infection. This finding suggests that in addition to
introduction of extracellular and periurethral bacteria 36, urinary catheter colonization can
occur from bacteria originating from pre-existing reservoirs or other niches within the
urinary tract not appreciated by assessment of bacteriuria. Interestingly, by day 5
following implantation in animals with a history of UTI, there is overall a significant
reduction in the number of QIRs compared to that in non-implanted animals as assessed
by bladder CFU. This reduction in bacterial load could be a result of enhanced immunemediated clearance of infected cells or to exfoliation of infected cells in implanted
animals. These hypotheses are currently being evaluated.
The identification of FimH as a critical virulence factor during UPEC CAUTI
provides an interesting avenue for the development of novel preventative measures
against these infections.

The results presented here suggest that the use of small

molecules inhibitors, such as mannosides, in combination with existing UTI treatment
regimes, can lead to prevention or delay of UPEC colonization. Mannosides, were
rationally designed to interfere with FimH-mediated binding to mannosylated proteins on
the surface of the uroepithelium84. Recent studies show that the use of mannosides in
combination with antibiotics is highly effective in preventing IBC formation and acute

103

stages of UPEC infection as well as treating chronic cystitis87. Similarly, pretreatment
with mannosides further prevents IBC formation following UPEC infection of implanted
bladders and reduces UPEC binding to the uroepithelium. However, the presence of the
abiotic implant surface provided a favorable environment for adherence of extracellular
bacteria. The inability of mannoside treatment to eliminate UPEC from the implant, given
that the experimental evidence that mannose inhibits UPEC biofilm on catheter material
in urine in vitro, may be due to the lack of urine flow in this implanted murine model. It
is possible that if it were possible to truly catheterize mice in a manner analogous to
clinical catheterization of humans in which urine flows through the catheter that
mannoside may have a more efficacious effect on implant clearance. Nonetheless, by
preventing invasion and shifting UPEC niche to the extracellular milieu, mannoside
enhanced the bacteriocidal efficacy of antibiotics, such as TMP-SMZ, which does not
cross host cell membranes. Mannosides could be used in combination with bacterial
interference strategy being offered as alternatives in the prevention of CAUTI. Previous
reports have shown that pre-colonization of urinary catheters with an avirulent E. coli
strain 83972 delays the onset of CAUTI in catheterized patients292. Thus, it is quite
possible that if used in combination with mannosides, UPEC will be kept from the
intracellular niche as well as from binding to the catheter during bacterial interference
with the avirulent strain. Though, the avirulent strain should be able to colonize the
catheter in a type 1-independent manner, which is not the case for E. coli strain 83972293.
The therapeutic effects of mannoside could not be recapitulated in our model of CAUTI
(data not shown), possibly because the small molecules are ineffective at disrupting
established biofilms in vivo. It is a well-established fact that the extracellular matrix of
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bacterial biofilms is impermeable to antimicrobial and antibiotics, providing a safe haven
for the microbes within42,54.
Urinary catheterization is a necessary medical procedure that causes major
damage to the urinary tract. Pathogens, such as UPEC, take advantage of this
compromised environment to exploit new and existing niches and establish severe
infections. This report uncovers important molecular mechanisms underlying UPEC
pathogenesis following urinary catheterization. It raises important questions regarding the
deleterious consequences of urinary catheterization and the origins of urinary catheter
colonization. These novel aspects of CAUTI pathophysiology should thus be taken into
consideration for the development of anti-virulence based preventative and therapeutic
approaches against these infections.
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DISCUSSION AND FUTURE DIRECTIONS
The management of CAUTIs has recently gained considerable interest in
healthcare settings20,21,56 due to the rise in multidrug resistant pathogens and given the
significant medical and societal burdens associated with these infections12,56. However,
the paucity of data describing the molecular mechanisms underlying the pathophysiology
of CAUTIs contributes to the high prevalence, difficult diagnoses, and ineffective
treatment regimens associated with these infections5,12.
In the present dissertation, in vitro biofilm assays and a murine model were
optimized to closely replicate the key characteristics of CAUTIs. These served as
valuable tools to unravel previously unappreciated details underlying the detrimental
effects of urinary catheterization on bladder homeostasis and revealed the microbial and
immunological factors contributing to enterococcal and UPEC establishment of CAUTIs.
Surprisingly, some in vitro biofilm determinants, such as Atn, GelE, and UPEC S pili
were not found to play a role in biofilm formation based on the CAUTI model whereas
enterococcal sortases and UPEC type 1 pili were major contributors of virulence.
Furthermore, studies revealed that the pathogenic cascade of UPEC is quantitatively
altered in presence of foreign bodies due to a multitude of factors in addition to urothelial
exfoliation5,12. Importantly, evidence presented in this dissertation show for the first time
that bacteria reservoirs in the bladder established during previous infections are a
potential third source for urinary catheter colonization. This is a risk that has not been
previously considered and has major implications for clinical management and decisionmaking in the context of CAUTIs and other medical-associated infections. Ultimately,
this study yielded insight towards the development of novel therapeutic approaches by
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establishing the efficiency of specific inhibitors of UPEC type 1 pili tip adhesin FimH,
namely mannosides, as alternative virulence-based preventative measures in the fight
against CAUTIs.
In addition to the milestones achieved in unraveling the molecular factors
involved in the pathogenesis of E. faecalis and UPEC CAUTIs and unappreciated aspects
of CAUTI pathophysiology, this dissertation has multiple ramifications and opens up
exciting avenues of research in various areas ranging from basic science research to
clinical management of CAUTIs and other biofilm-associated infections.
Implications for enterococcal and UPEC pathogenesis:
Findings from this dissertation represent advance our understanding in the study
of E. faecalis uropathogenesis as well UPEC pathogenesis in the context of urinary
catheterization. Biofilm formation on the surface of urinary catheters, a central
component of CAUTIs, was demonstrated here to be an essential virulence property for
E. faecalis colonization of and persistence within the urinary tract. In vitro studies
performed in this work showed that the enterococcal autolytic factor Atn mediates DNA
release at a specific time during the establishment of DNA-dependent E. faecalis
biofilms. Extracellular DNA (eDNA), was found to be a major component of the
extracellular matrix of enterococcal biofilms in vitro, and to be critical for the maturation
and architectural stability of these structures. These findings are in agreement with
previous reports by Thomas et al, which showed that gelatinase (GelE) contributes to
DNA release during biofilm formation by regulating autolytic processes probably via
cleavage of Atn103,104. GelE is a well-established virulence factor in a rabbit model
enterococcal endocarditis where biofilm formation occurs on the surface of heart
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valves221. Yet, Atn and GelE were dispensable for biofilm formation and virulence in the
urinary tract in the CAUTI model. These findings question whether eDNA is important
for biofilm formation in the urinary tract. Investigation of the regulation of autolytic
processes in E. faecalis will help uncover complementary pathways involved in DNA
release, as DNA-dependent biofilm formation may be critical in other enterococcal
infections and in an agricultural environment221,294. Furthermore, E. faecalis may employ
eDNA-independent pathways to establish biofilms on the surface of urinary catheters.
The enterococcal factors identified to promote biofilm formation and virulence in
the urinary tract were sortases SrtA and SrtC, the enhanced expression of pheromone
protease (Eep), and the transcription factor AhrC. Thus, sortase substrates, which are cell
surface proteins, may represent attractive targets for antimicrobial therapies given their
ubiquitous nature and various functions in bacterial physiology and pathogenesis116,143. E.
faecalis encodes over 30 LPxTG motif containing proteins116, including the endocarditis
and biofilm-associated pilus (Ebp), a structure which contributes to enterococcal UTI
pathogenesis107 (Nielsen, H.V., Guiton, P.S., et al, manuscript in preparation). Expression
studies in vitro and in vivo and direct mutagenesis of candidate genes may help uncover
relevant biofilm and urovirulence-promoting substrates. As for UPEC, of the known
biofilm determinants examined, including the amyloid fibers curli and S pili, only type 1
pili were found to be essential for biofilm formation and virulence in the murine model of
foreign body associated UTIs.
The physiological requirements to produce and maintain biofilms in the urinary
tract require further research. Genetic and biochemical approaches can be used to
uncover the molecular details of the interactions within biofilm communities. Microarray
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analyses of cells extracted from in vivo biofilms at different time during the infection
process can identify genes that are important for metabolic processes, extracellular matrix
formation, or immune evasion during CAUTI. In addition to microarray analyses
following infections, identification of SNPs between E. faecalis OG1RF and OG1X
strains can provide potential candidates for novel biofilm determinants and virulence
factors. In collaboration with Kimberly Kline, Ph.D., Fredrik Henriques and Brigitta
Henriques-Normark, M.D., Ph.D., 69 SNPs were identified in coding regions between the
two strains and 11 were sequenced and confirmed (Tables 1 and 2). These genes have
putative functions ranging from cell surface proteins to energy transduction. Investigation
of their roles to E. faecalis biofilm and virulence will provide more insights into the
drastic defect observed with OG1X in vivo.
Furthermore, the composition of the extracellular matrix of both E. faecalis and
UPEC biofilms can be determined by isolating the matrix of biofilms from the surface of
urinary implants from mice and from urinary catheters isolated from human patients and
analyzing them using and optimizing previously established methods65. The molecular
basis of how these structures change overtime can be investigated to provide insight into
the biofilm developmental processes. Ideally, the constituents of these extracellular
matrices, if identified and characterized, can be useful targets for the disruption and
dissolution of biofilms on the surface of urinary catheters.
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Table 1: List of the putative functions of the 69 SNPs identified in coding
regions between OG1RF and OG1X
Putative functions
Replication

Number of
different
genes
1

Putative functions

Transcription

8

Translation

3

Lipid transport and
metabolism
Transport, unknown
substrates
Energy metabolism

1

Membrane/cell wall

3

Signal transduction

10 with 2
putative
SrtA
substrates
1

8

Defense mechanism

4

4

Unknown function
and hypothetical
proteins

17

Inorganic transport

Number of
different
genes
1
4
4

Nucleoside transport and
metabolism
Amino acid transport and
metabolism
Carbohydrate transport and
metabolism
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Table 2: List of 11 genes with sequenced and confirmed SNPs between OG1RF and OG1X
Gene with confirmed
SNPs
EF0243

Putative function
Branched-chain amino acid transport system
II carrier protein (bnrQ)

AA Change
OG1RF  OG1X
Val Iso

EF3157

Glycosyl hydrolase, family 65

Ser Asn

EF1513

Pheromone binding protein

Ser Asn

EF1218

Spermidine/putrescine ABC transporter,
permease protein

Pro Ser

EF2575

Carbamate kinase

Gly Asp

EF2983

Glutamyl-tRNA(Gln) amidotransferase, A
subunit, putative

Ala Thr

EF3285

PTS system, IIC component

Ser Phe

EF3290

Sensor histidine kinase

Glu Lys

EF1778

Phosphoribosylaminoimidazolecarboxamide
formyltransferase/IMP cyclohydrolase
(purH)
Inosine-uridine preferring nucleoside
hydrolase

Arg Gln

Glycosyl hydrolase, family 13

His Tyr

EF2587
EF1349

Arg Thr

Remarkably, the establishment of persistent enterococcal and UPEC CAUTIs
occur despite the induction of an acute inflammation response following urinary
catheterization. The host immune response within the catheterized murine bladder
consists of the onset of massive bladder wall edema due to an increased in vascular
permeability, the production of pro-inflammatory cytokines, and the recruitment of
myeloid cells, especially neutrophils. This robust response fails to prevent and clear
bacterial infection. One hypothesis is that the acute immune response to a urinary catheter
alters the adequate response to uropathogens or favors biofilm formation as shown for
Methicillin-Resistant S. aureus295. Unlike E. faecalis, UPEC induces a robust
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inflammatory response in non-catheterized animals76,190,239. Comparison of this immune
response to that elicited during UPEC-mediated CAUTI can provide insight into the
above hypothesis. Alternatively, E. faecalis and UPEC may employ several molecular
immune evasion mechanisms to withstand and escape the deleterious effects of the
immune system activated during CAUTI, such as subversion of neutrophil killing,
invasion into the host cells260,261,266,269,296-298, or incorporation of host-derived components
to produce biofilms as shown for Nontypeable Haemophilus influenza157,299, thus
potentially rendering the biofilms less immunogenic.
This dissertation focused on the immune response 24h following urinary
implantation with or without bacterial challenge. It will be informative to examine the
changes of the immune response over time. This can be achieved by microarray and
quantitative real time PCR analyses of bladder cells at different times following urinary
implantation in the presence or absence of the bacteria of interest. Not only will these
experiments allow the identification of the immune pathways leading to bladder
inflammation after catheterization, they will help uncover the effects of bacterial
colonization on these immune pathways. A pathway that is activated in response to
bacteria and detrimental to the infectious agent can be modified and exploited for
enhancing the antibacterial response whereas infection-promoting pathways could be
targeted for downregulation or inhibition.
It will be of great interest to investigate the mechanisms underlying UPEC and
enterococcal dissemination to the kidneys as well as the complications ensuing from
urinary catheterization, including pyelonephritis and bacteremia. The onset of edema may
cause reflux to the kidneys300, and hence may promote bacterial colonization of these

112

organs. On the other hand, bacteria may have mechanisms to hijack the host cells and
disseminate to other organs. The role of the host in bacterial dissemination can potentially
be addressed following experimental depletion of host immune populations of interest.
Implications for microbial physiology and intra- and inter-microbial interactions:
CAUTIs are polymicrobial in nature37,57,58. Thus, these studies should be extended
to mixed microbial communities given that the molecular interactions within constituents
of polymicrobial communities on the surface of urinary catheters are poorly defined. Are
all microbes found together or in specific consortia? Do they interact with each other to
the same extent? Is there particular microbial associations during CAUTI progression as
suggested by Macleod et al.58? What are the molecular factors underlying these
preferential associations? Is the host immune response altered in presence of various
bacteria? Is the host response to one pathogen favorable or detrimental to another?
Introduction of other uropathogens such as P. aeruginosa, P. mirabilis, and other Grampositive bacteria while studying CAUTI will contribute to a better understanding of the
intra and inter-species interactions occurring during these infections.
It is proposed that E. coli and Enterococci are among the first to colonize urinary
catheters and the microbial population is altered over time with colonization by P.
aeruginosa, P. mirabilis, Providencia stuartii, Morganella morganii37. Data obtained in
the course of this thesis indicate that live E. coli UTI89 and supernatants from stationary
E. coli cultures inhibit enterococcal biofilm in vitro (Fig. 41A-C, Guiton et al,
unpublished). Similar findings were obtained with the commensal E. coli strain MG1655
(data not shown). On the other hand, UPEC does not affect E. faecalis biofilm formation
and virulence in vivo when introduced at a 1:1 ratio in implanted animals (Fig. 41D-E;
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Guiton, P.S. et al, unpublished). Both bacterial species are recovered on the surface of
implants and organs to the same extent as in single infections. Similar results were
obtained in the kidneys (data not shown). Together, this indicates that the molecular
dynamics of in vitro and in vivo biofilm formations in mixed communities are different.
Identification of the E. coli in vitro inhibitory factor(s) may represent a target to prevent
in vivo infections. Studies from the K2 pyelonephritis isolate CFT073 identified an
inhibitory polysaccharide fragment301. However, UTI89 and MG1655 produce K1 and
K12 capsules, respectively302,303, suggesting the inhibitory factor identified in the present
study is unique. It will be of interest to understand why UPEC does not inhibit
enterococcal biofilms in vivo. Can it be that the anti-biofilm substance(s) is/are not
produced in the urinary tract, produced and degraded, or present in too minute quantities
in vivo to be effective against E. faecalis biofilms? Further research on this topic will
contribute to a better understanding of the interactions between UPEC and E. faecalis and
provide insight into potential novel anti-biofilm agents against enterococcal biofilms.
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Figure 40: Differential interactions between E. faecalis and UPEC in vitro and in vivo.
Representative CLSM images of (A) single and mixed OG1RF and UTI89 dynamic biofilms in
TSBG and (B) of OG1RF shaking and static biofilms grown in TSBG supplemented with
minimal media (M63+niacin+glycerol) or filter-sterilized UTI89 supernatants from stationary
cultures in minimal media grown for 48h on PVC coverslips at 37ºC. SYTO89 and PI were used
to stain bacterial DNA in all experiments. In mixed biofilms, OG1RF was stained additionally
with WGA (pink punctuates in middle panel in A). (C) Crystal violet based quantification of 24h
OG1RF biofilms grown in TSBG supplemented with either minimal media or UTI89 supernatant.
Error bars =SEM from two independent experiments. (D-E) Graphs represent bacterial titers in
log scale from implants and bladders of animals inoculated for 24 and 48h with OG1RF (●),
UTI89 (■), or a mixture of OG1RF (○) and UTI89 (□) at a 1:1 ratio. Horizontal dashed lines
represent LOD for viable bacteria. The horizontal bars represent the median of each dataset;
*p<0.05, **p<0.0005, ***p<0.0005, ns corresponds to p>0.05 by the Mann Whitney U test.
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Implications for bladder cell biology and physiology:
The presence of a foreign body within the urinary tract alters the bladder
environment and homeostasis, resulting in cellular proliferation, urothelial damage,
increased exfoliation, and the induction of a massive inflammatory response. All these
detrimental biological changes may lead to bladder carcinogenesis, as in the case of
patients with spinal cord injuries who are at higher risk of developing bladder cancer
following urinary catheterization27,180,181. Important questions regarding the rate of
bladder exfoliation, urothelial cell division and differentiation, and the epithelial
responses to urinary catheterization could possibly be addressed by comparing responses
following bladder implantation in animals with different genetic backgrounds. Further
research may be warranted to investigate the development of bladder tumors following
urinary catheterization. Simply, to start, the effects of urinary catheterization could be
assessed on the production and function of several known markers of bladder cancer,
such as RhoGDI2304 and Oct-3/4305. Additionally, further optimization of the murine
model of CAUTI is required to ensure long term catheterization that may provide a novel
tool for the study of urothelial tumorigenesis and metastasis in mice, similar to a previous
model developed by Reis et al, but without involving the transurethral introduction of
human carcinoma cells as in the orthotopic models of bladder cancers306 or administration
of chemicals such as organic arsenicals in the bladder307,308. Understanding the
consequences of urinary catheterization on bladder homeostasis may provide insights into
the damage and side effects resulting from this necessary medical process.
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Clinical implications
The findings from this work question the very answer to “What is a UTI?” The
current clinical definition refers to UTI as “the presence of bacteria within the urinary
tract”5 and even with the different classifications of UTIs, undoubtedly does not
encompass all the variations and presentations the disease can take. CAUTIs are rarely
symptomatic; yet, bacteriuria, which is almost inescapable following urinary
catheterization12, and pyuria. Pyuria is not a good correlate of CAUTIs22. The
establishment of intracellular niches in the presence of urinary catheters is a major
discovery in the pathophysiology of UPEC-mediated CAUTI (Chapter three). Thus,
bacterial counts equal to or greater than 1000 CFU/ml and pyuria, which occurs
regardless of microbial colonization, as demonstrated here, are not enough for defining
appropriate treatment course for intracellular microbial populations. It is thus imperative
to identify new diagnostic tools in order to have better preventative or therapeutic
regimens for CAUTI patients. Work outlined herein establishes a new origin for catheter
colonization, in addition to the intraluminal and extraluminal portals178, implying that
patients with history of UTIs may be at greater risk of CAUTI and rUTIs after catheter
removal. The favored CAUTI treatment strategy, which is the removal of contaminated
urinary catheter following bacteriuria, should be reconsidered in light of the findings
presented here. Intracellular bacteria or pre-existing reservoirs from previous UTIs can
resurface and cause recurrent infection even in the absence of catheters. It is thus
imperative to re-examine the paradigms for diagnosing and treating CAUTIs.
In addition to leukocyte esterase and nitrite currently used as biomarkers of
UTIs309, it will be very advantageous to have additional host and bacterial biomarkers
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that provide more insights into the type of infection and the stages of the disease. These
biomarkers may include small molecules produced by multidrug resistant bacteria or the
host immune cells during infections and biomaterials shed from biofilms during
infections that can be detected in the urine. Bacterial DNA, polysaccharide fragments
from the extracellular matrix of biofilms or particular proteins from the host secreted only
in the presence of particular bacterial species may be among these biomarkers.
Furthermore, this thesis shows that immunosuppression favors enterococcal infections,
since

dexamethasone

corroborating

the

treatment

predominance

and
of

neutrophil
CAUTI

depletion
among

enhance

infections;

immunosuppressed

and

immunocompromised individuals5. This finding also implies that immunosuppression in
a patient undergoing urinary catheterization should not be a favored approach in trying to
reduce the inflammation and other side effects ensuing from catheterization or during the
treatment regimens against CAUTIs.
Drug development
CAUTIs originate primarily from multidrug resistant bacteria. The identification
of intracellular populations, as in the case of UPEC CAUTI coupled with the everincreasing antibiotic resistance, especially within biofilms, underscores the need for
better preventative and therapeutics approaches. As demonstrated in this dissertation,
mannosides, which specifically target the FimH adhesin of UPEC, prevented the
establishment of IBCs and, in combination with existing antibiotic-based therapy,
prevented the establishment of implant and organ colonization in the murine model of
CAUTIs. Thus, virulence-based approaches in addition to antimicrobial-coated catheters
or bacterial interference approaches as previously proposed293,310 can be novel avenues of
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research for preventing and treating CAUTI. Surface proteins, such as LPxTG motifcontaining cell wall proteins in Gram positive bacteria, are also attractive targets for
virulence-based approaches as they are readily accessible, important for binding to
abiotic surfaces as well as urothelial cells, and can be mediators of bacterial immune
evasion.
Studies in this thesis also demonstrated that urinary catheterization induces
urothelial damage and significant reduction in UPEC IBC formation. It is thus plausible
that the use of abiotic irritants that induce urothelial exfoliation and/or release antibiofilm agents such as mannosides in a controlled manner may be an effective treatment
for women suffering from chronic and recurrent UTIs. It will be of interest to evaluate
chemicals or devices that can enhance bladder exfoliation to remove intracellular
reservoirs without favoring microbial colonization and causing further damage to the
bladder. Such strategy may be helpful to reduce the rate of recurrent infections.

CONCLUDING REMARKS
CAUTIs are major nosocomial infections afflicting humans of both sexes and all
ages and associated with important medical and societal burdens. The present dissertation
provides a better understanding of these infections, particularly caused by UPEC and E.
faecalis, using an optimized murine model of CAUTI. The study presented here describe
important characteristics of CAUTIs, raise important questions regarding diagnostic
approaches and propose novel preventative and therapeutic approaches against CAUTIs
based on the identification and targeting of important biofilm determinants and virulence
factors. The implications of the current report underscore the need for more research and
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increased clinical attention to CAUTIs for a better management of these infections and
ultimately the patients’ welfare.
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MATERIALS AND METHODS
Bacterial strains and growth conditions
All strains used in this study and their characteristics are listed in Table 3.
For E. faecalis: Unless otherwise specified, all experiments were initiated from an
overnight culture in brain heart infusion broth (BHI; Becton Dickinson, Franklin Lakes,
NJ) of a single bacterial colony grown on BHI agar plate supplemented with the
appropriate antibiotics. Liquid cultures were grown statically at 37°C for 18 hours.
For E. coli: bacteria from a single colony from Luria Bertoni (LB, Becton Dickinson)
agar plate supplemented with the appropriate antibiotics were inoculated into LB broth
and grown statically at 37°C for 18 hours or 2 x 24h.
Antibiotics used for bacterial selection: Rifampicin (Rif), Fusidic acid (Fus), Kanamycin
(Kan), Chloroamphenicol (Cm), and Streptomycin (Str); from Sigma-Aldrich, Inc., St.
Louis, MO.
Genetic manipulations and sequencing
Table 4 lists the plasmids used in this study.
For E. faecalis: In-frame deletion constructs were made in temperature sensitive plasmid
pJRS233311,312 for genes of interest based on the complete genome of E. faecalis V583313;
all references to genomic loci below are based on this annotation (GenBank accession
number AE016830). Chromosomal integrants were selected as previously described314
with primers listed in Table 5. Complementation of indicated genes was done using a
pABG5-derived pAL1 plasmid expressing the gene of interest under the rofA
promoter312,314,315.
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For E. coli: Genetic mutations were generated as previously in described using λ Red
Recombinase system316,317.
DNA sequencing and sequence manipulations
Genes of interest were separately amplified in PCR reactions using OG1RF and OG1X
colonies or purified genomic DNA as template. The primers used for amplification are
listed in Table 7. Forward (F1 or 2) primers were used for amplification of the upstream
region and Reverse (R1) primers were for amplification of the downstream region of the
genes of interest annotated according to the genome sequence of E. faecalis V583313.
PCR were performed as described in Chen et al318. Products were purified using the
QIAquick PCR purification kit according to manufacturer’s guidelines (Qiagen) and
submitted for capillary sequencing with primers listed in table 7 using an ABI 3730xl
instrument (Genewiz, Inc.). Base calling and assembly was done using Phred and
Phrad319,320. Sequences were aligned using CLUSTAL W321 with default parameters and
trimmed to the start and stop codons of genes as annotated in the OG1RF and V583
genome sequences168,313.
Inhibitors and chemicals
The drug treatments used in this study, their relevant modes of action, and references of
dosage and effectiveness are described in Table 7. Vehicles were saline or DMSO as
indicated.
Mouse strains
Six to seven week-old female wild-type C57BL/6Ncr mice purchased from the National
Cancer Institute (NCI) were used in this study. Six to seven week old female C57BL/6J,
interleukin 6 mutant B6.129S-IL6tm1kopf/J (referred to in this study as IL6-/-), Toll Like
122

Receptor 2 mutant B6.129-Tlr2tm1Kir/J (referred to in this study as TLR2-/-), Rag
B6.129S7-Rag1tm1Mom/J mice were obtained from Jackson Laboratories. MyD88, Trif, and
cKit-mutant female mice from Jackson Laboratories were bred at Washington University
in St Louis. Experiments were performed following one-week adaptation in the animal
facility. All studies and procedures were approved by the Animal Studies Committee at
Washington University School of Medicine.
Cultivation and quantification of biofilms
Bacterial preparation for biofilms: Stationary phase bacteria from overnight cultures
were diluted to OD600 of 0.2 in fresh growth medium followed by an immediate 1:100
dilution (1-2x106 CFU/ml) in biofilm media: TSBG composed of tryptic soy broth (TSB;
Becton Dickinson, Sparks, MD) supplemented with 0.25% of glucose (Sigma-Aldrich),
LB, or human urine. Urine was collected from healthy volunteers as approved by the
Institutional Review Board of Washington University in St. Louis. Pooled urine were
spun at 10,000 x g for 15min, filtered through 33µM filters, and, if necessary, stored at
4ºC for no more than 3 days. Mixed biofilms were grown in TSBG with bacterial strains
mixed at a 1:1 ratio prior to media inoculation. Supernatants from stationary phase UTI89
cultures grown in minimal medium (M63 salts with niacin and glycerol) or LB under
static conditions at 37ºC were spun at maximum speed, filter-sterilized, and were added
to TSBG at 1:4 ratio (20% supernatant to 80%TSBG) prior to OG1RF inoculation.
Supernatants from stationary cultures of OG1RF in BHI and sterile minimal medium, LB,
and BHI were supplemented to TSBG when indicated and used as controls.
Coverslip-based assays: Biofilms were grown as described by Gilmore et al.322 and
modified as follow: 5ml of diluted cultures were placed in each well of sterile 6-well
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tissue-culture flat bottom plates (Techno Plastic Products, St Louis, MO) containing a
UV-sterilized 22x22mm plastic cover slip (Fisher scientific, Pittsburgh, PA). Plates were
incubated at 37°C statically or under dynamic conditions (100RPM) on an orbit shaker
(model 3520; Lab-Line Instruments, Inc., Melrose Park, IL) for the duration of the
experiments. At 24hr intervals, media were removed by aspiration and the cover slips
were washed twice with 5ml of autoclaved water for 3 minutes at 100RPM on orbit
shaker at room temperature (22-25°C) and fresh media added. At selected time points,
biofilms were washed and air-dried. Biofilms were then stained with 0.5% crystal violet
(Sigma-Aldrich, Inc., St Louis, MO) for 10 minutes at room temperature. Excess dye was
removed with autoclaved water and air-dried at room temperature. Biofilms were then
dissolved with 500µl 33% acetic acid (Fisher Scientific, Fair Lawn, NJ). Biomass was
quantified colorimetrically by measuring the absorbance at OD595 with a microplate
reader (Molecular Devices, Sunnyvale, CA). Experiments were performed independently
at least three times with three coverslips/condition/experiment.
Fluid flow-based assay: Biofilms were grown as described by Ferrieres et al.323on All
Silicone Foley catheters (Bard Medical, GA) or silicone tubing (Thermo Fisher Scientific
Inc.) and modified as follows. All tubing and connectors in the system were autoclaved
and ethanol sterilized prior to use. The system was assembled similar to the previously
described flow-chamber system. Priming of the catheter or the silicone tubing occurred
at 37ºC for 20min by flowing pre-warmed pooled human urine. Pooled samples were
spun at 10000xg for 15min, filtered through 33µM filters, and, if necessary, stored at 4ºC
for no more than 3 days.

Three milliliters of stationary-phase E. coli from

overnight cultures were diluted to 1-2x106 CFU/ml in human urine and injected into the
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catheter or silicone tubing using a 30 cc gauge needle. The bacteria were allowed to
attach to the substratum for 1 h before urine flow via Watson-Marlow peristaltic pump
205S was resumed at 0.5 ml min−1. When indicated, urine was supplemented with 1%
methyl-α-D-mannopyranoside (Sigma-Aldrich) prior to the experiment. After 24 hours,
the remaining medium was exchanged for sterile ddH2O that was allowed to flow at 0.5
ml min−1to remove residual urine and non-adherent bacteria in the system. The liquid
from catheter or silicone tubing was then removed by capillary action onto absorbent
paper. The tubing was cut into pieces for CFU enumeration or crystal violet staining,
respectively. For CFU enumeration, at least three pieces (1cm in length) of incubated
tubing were separately further cut into smaller pieces and placed into 1ml PBS. Adherent
cells were detached by sonication (10min) and vigorous vortexing (3min). Viable
bacterial counts were assessed by serial dilution on BHI or LB agar plate with appropriate
antibiotics. Crystal violet staining was used to determine biofilm biomass. At least 3
pieces of incubated tubing (3cm in length) were filled with 0.5% crystal violet at room
temperature for 10 min. Excess dye was removed by washing three times with ddH2O
and dried by capillary action on absorbent paper. The bound crystal violet was then
dissolved in 200 µl of 33% acetic acid and absorbance measured at 595nm. The amount
of biofilm was expressed as CFU/ml per cm2 and A595/cm2. The experiment was
repeated at least twice with different urine samples.
Primary adherence assay
Biofilms were set up according to the coverslip-based assay described above. Cells were
allowed to attach for 2h, 4h, and 6h at 37°C under static or shaking conditions. After
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desired incubation times, cover slips were washed once with sterile water and processed
as described above. Adherent cells were quantified by OD595 measurements.
DNase I assays
DNase I (Sigma Aldrich) or heat inactivated DNase I (30 minutes at 100°C) was added at
a final concentration of 5µg/ml, unless otherwise stated in coverslip-based biofilm assays.
Heat-inactivation of DNase I was verified by its inability to digest 100µg/ml of salmon
sperm DNA or purified enterococcal genomic DNA in TSBG for 1h or 24h at 37°C.
DNase I was either supplemented continuously every 24hrs from the beginning of the
experiment or added to preformed biofilms for the time indicated. Experiments were
performed independently in triplicate with three cover slips/condition/experiment.
Bacteria and biofilm visualization
By Confocal Laser Scanning Microscopy: All confocal microscopy was performed on
an LSM 510 Meta Laser Scanning Confocal microscope (Carl Zeiss, Thornwood, NY),
using a 63X oil immersion objective. Images were acquired using the LSM Image
Examiner software (Carl Zeiss, Thornwood, NY). 3D reconstruction of biofilm images
were generated using Volocity software (Improvision, Inc., Waltham, MA). Washed
plastic cover slips were stained for 15 minutes in the dark at room temperature with 1ml
of 3µM of SYTO9 mixed with 3µM of propidium iodide (PI) from Molecular Probes,
Eugene, OR.

When indicated, 1µg/ml of Alexa Fluor 633-conjuaged Wheat Germ

Agglutinin (WGA) was added for carbohydrate staining324. Excess dye was removed by
aspiration and biofilms were washed twice with 1X phosphate buffer saline (PBS)
solution or water. Stained cover slips were mounted on glass slides using Prolong® Gold

126

Antifade (Molecular Probes) followed by image acquisition. Microscopy was performed
on two coverslips/condition/experiment with at least two independent experiments.
By Freeze Dry Electron Microscopy: Biofilms grown on glass cover slips in TSBG
under hydrodynamic conditions for 48h on were fixed with 2% glutaraldehyde in 100mM
NaCl, 30mM Hepes, 2mM CaCl2 and 75mM Sucrose, pH 7.2 for 1 hour. Samples were
rinsed in deionized water to remove aldehyde and buffer, and quick-frozen by forceful
impact against a copper block cooled to 4°K with liquid helium. Frozen cultures were
stored in liquid nitrogen until mounting in a Balzers 301 vacuum evaporator, wherein
they were freeze-dried for 20 minutes at –80°C and then rotary-replicated with 2 nm of
platinum deposited from an electron-beam gun mounted at 15 degrees above the
horizontal. The Pt-replica was then stabilized with a carbon film deposited from a 70°
angle. Replicas were floated off the glass onto concentrated hydrofluoric acid, then
transferred through several rinses of deionized water and picked up on formvar-coated
grids. Replicas were examined in a JEOL 100CX microscope and photographed with an
AMT digital camera.
By Transmission Electron Microscopy: For immunolocalization of DNA at the
ultrastructural level, 48h dynamic biofilms were fixed in 4% paraformaldehyde/0.05%
glutaraldehyde (Polysciences Inc., Warrington, PA) in 100mM PIPES/0.5mM MgCl2, pH
7.2 for 1 hr at 4°C.

Samples were then embedded in 10% gelatin and infiltrated

overnight with 2.3M sucrose/20% polyvinyl pyrrolidone in PIPES/MgCl2 at 4°C.
Samples were trimmed, frozen in liquid nitrogen, and sectioned with a Leica Ultracut
UCT cryo-ultramicrotome (Leica Microsystems Inc., Bannockburn, IL). 50 nm sections
were blocked with 5% Fetal Bovine Serum (FBS)/5% Normal Goat Serum (NGS) for 30
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min and subsequently incubated with mouse anti-double-stranded DNA (anti-dsDNA)
monoclonal antibody (Abcam, Cambridge, MA) for 1 hr at room temperature. Sections
were then washed in block buffer and probed with 18nm colloidal gold-conjugated antimouse secondary antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove
PA) for 1 hr at room temperature. Sections were washed in PIPES buffer followed by a
water rinse, and stained with 0.3% uranyl acetate/2% polyvinyl alcohol. Samples were
viewed with a JEOL 1200EX transmission electron microscope (JEOL USA Inc.,
Peabody, MA). All labeling experiments were conducted in parallel with controls
omitting the primary antibody.

These controls were consistently negative at the

concentration of colloidal gold conjugated secondary antibodies used in these studies.
Quantification was based on gold particles labeling from 13 independent fields at 30000X
magnification.
By Negative staining and analysis by electron microscopy: Bacteria were grown
overnight in BHI and diluted as described above in TSBG. They were allowed to grow
statically for 6h at 37°C. Cells were pelleted and resuspended in 1X phosphate buffered
saline (PBS). Bacteria were allowed to absorb onto formvar/carbon-coated copper grids
for 1 min. Grids were washed in dH2O and stained with 1% aqueous uranyl acetate (Ted
Pella Inc., Redding CA) for 1 min. Excess liquid was gently wicked off and grids were
allowed to air dry. Samples were viewed on a JEOL 1200EX transmission electron
microscope (JEOL USA, Peabody, MA) at an accelerating voltage of 80kV.
By Scanning Electron Microscopy: Biofilm grown on silicone tubing were fixed in 4%
paraformaldehyde, 2.5% glutaraldehyde, and 0.1M cacodylate, and prepared for scanning
electron microscopy (Hitachi Ltd, Tokyo).
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Cellular autolysis assay
The autolysis assay was performed as previously described in sodium phosphate buffer
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. Briefly, overnight cultures were inoculated in fresh TSBG at a final O.D. of 0.002 at

600nm and grown at 37°C on an orbit shaker at 100RPM to an O.D. of 0.6 at 600nm or
after 24h. Cultures were then placed on ice for 10 min and 1.5ml were removed and
centrifuged at 14,000 x g for 5min at 4°C. The supernatants were discarded and the
pellets were resuspended in 1.5ml of ice cold water and washed thrice at 14,000 x g for
5min at 4°C. Subsequent to the third wash, the pellets were resuspended in 10mM
sodium phosphate buffer at pH 6.8 supplemented with 0.5µg/ml of trypsin (SigmaAldrich). 200µl of the suspensions were dispensed in a 96-well flat bottom microtiter
plates in quintuplet and the remaining wells were filled with ddH2O. Samples were
incubated at 37°C and O.D. readings were taken every 30 minutes for up to 9 hours at
600nm in a spectrophotometer. Autolysis was expressed as percent of initial turbidity at
600nm.
Murine implantation procedure
The experimental model for foreign-body associated UTI 29,194 was adapted for the study
of E. faecalis and E. coli with the following modifications. Polyethylene tubing (PE10
outside diameter, 0.6mm, inner diameter, 0.28mm; Becton Dickinson, MD) and
platinum-cured silicone tubing (SIL025: outside diameter, 0.64mm; inside diameter,
0.30mm; Braintree Scientific, Inc, MA) were sterilized with 70% ethanol and air-dried.
A seven-millimeter-long segment of PE10 was fitted onto a 30.5-gauge sterile needle
(Becton Dickinson). A four to five millimeter-long straight segment of the SIL025 was
then placed on top of the PE10 segment. The assembly was then UV-sterilized for 24h.
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Seven to eight week-old female wild-type C57BL/6Ncr mice were anesthetized with
inhaled isoflurane and placed on their backs. The periurethral area was sterilized with
100% ethanol and 10% povidine-iodine solution. The needle with both PE10 and SIL025
was gently inserted in the urethral opening. The long segment (PE10) was delicately
advanced with tweezers until the shorter segment (SIL025) was released into the bladder.
Subsequently, the needle with the PE10 was removed leaving the silicone implant in the
murine bladder. The recovery of straight silicone implants was greater than 95% at 24
hours and approximately 75% seven days following implantation.
Bacterial infection and colony forming unit (CFU) determination
Bacterial cells were collected from overnight cultures by centrifugation at 8,000 X g for 5
min and resuspended in 1x phosphate-buffered saline (PBS) to an approximate optical
density at 600nm of 1 corresponding to approximately 7x108 CFU/ml. When indicated,
bacteria were further diluted to OD600 of 0.5. Seven- to eight- week-old female
C57BL/6Ncr mice with or without silicone implant were anesthetized by inhalation of
isoflurane and infected by transurethral catheterization as previously described62,325 with
50µl inocula of PBS or bacterial suspensions (~1-3.5x107 CFU) immediately following
implantation. For polymicrobial infections, bacterial species were mixed at a 1:1 ratio to
reach (~1-2x107 CFU/strain). To quantify bacteria present on implants and in mouse
organs, mice were sacrificed at desired time points by cervical dislocation after
anesthesia inhalation, and the bladders and kidneys were aseptically harvested.
Subsequently, the silicone implant was retrieved from the bladder when present, placed in
PBS, sonicated for 10 min and then vortexed at maximum speed for 3 min. Bladder and
pairs of kidneys from each mouse were homogenized in PBS. For bacterial enumeration
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on implants and tissues, samples were serially diluted and plated on BHI supplemented
with the appropriate antibiotics or LB plates. Colony forming units (CFU) were
enumerated after 24h incubation at 37˚C. Experiments were performed at least twice with
n=5 mice/strain/condition. Biofilms on retrieved implants were visualized by scanning
electron microscopy at indicated time points.
Bladder weight determination and plasma protein extravasation
When indicated, bladders were aseptically removed, bisected, and blotted dry. Bladders
were placed in pre-weighed eppendorf tubes and weighed. Bladder weight (in grams) was
determined as the difference between bladder and eppendorf tube weight and that of the
empty eppendorf tube.
Plasma protein extravasation (PPE) in the bladder was determined using the Evans blue
technique326 in non-implanted and implanted animals at 6h post treatments with indicated
chemicals listed in Table 6. Mice were anesthetized by inhalation of isoflurane and
30mg/kg Evans Blue (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was administered
intravenously (i.v.). Animals were sacrificed 15 min later by cervical dislocation. The
bladder was then excised, bisected, and blotted dry before weighing. Bladders were then
placed in 1ml of 100% formamide (Sigma-Aldrich) and incubated at 60ºC for 24 h for
Evans blue extraction. The extracted Evans blue from each bladder was quantified by
colorimetric measurement at 620 nm with an automated microplate reader. The dye
content extravasated in each bladder was determined from an Evans blue standard curve
and expressed as µg/g of tissue.
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Mass spectrometry analysis
To assess the presence of substance P following urinary catheterization, non-implanted
and implanted animals with and without bacterial infections (one/experimental group)
were sacrificed 3hpi. Bladders were retrieved, homogenized, spun at maximum speed to
pellet cellular debris, and bladder homogenates were frozen at -80ºC until further use.
Substance P is an undecapeptide with a molecular weight of 1347.6 and synthetic
Substance P was purchased from Santa Cruz Biotechnology and used as positive control.
Under routine electrospray conditions described below the 2+ and 1+ ions at 674m/z and
1347m/z respectively dominate the spectrum. The peptide does not fragment to yield a
nice sequence of ions but rather only seems to lose H2O and the C-terminal methionine.
The ms2 spectrum has two major ions m/z 600, which is the b102+ and m/z 666 the b112+.
The y9 (m/z 1095) and b2 (m/z 254) are also present to a lesser extent. This is in
agreement with the literature327.
C18 SPE columns (Waters, Milford, MA) were used to cleanup bladder homogenates and
synthesized Substance P control. Substance P elutes in a 50% MeOH fraction. Samples
were then applied to the SPE columns and the columns were washed (W) and then eluted
(E). SRM scans were run on all W and E fractions but Substance P was not detected.
The mass spectrometer used for the study was a Thermo-Finnigan LCQ Deca coupled to
a Waters capLC. Samples were injected onto a Vydac C18 MS column (150mm 0.3mm
X 5u) with a flow rate of 6ul/min. At time 0 Solvent A (0.1% formic acid) was held at
92% and solvent B (80% acetonitrile in 0.1% formic acid) at 8%. Initial conditions were
held constant for 5 minutes, before beginning a linear gradient which increased to 85% B
in the next 45 minutes. The column was allowed to equilibrate for 15 minutes before
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starting the next run. The spray voltage on the spectrometer was 4.5K and the capillary
temperature was 200 ºC. For CID experiments helium was used as the collision gas with
the collision energy set to 30% of the maximum (~5 eV). Spectra were recorded from m/z
216-2000 in the positive centroid mode. Ions were monitored with a window of +/0.5amu
Cytokine profiling
Bladder homogenates from non-implanted and implanted animals with or without
bacterial infections were microcentrifuged at 14,000 r.p.m. for 5 min and supernatants
frozen at −80°C until the time of the assay. Assays were carried out according to
manufacturers' protocols using the Bio-Plex Pro Mouse Cytokine 23-plex Assay kit from
Bio-Rad Laboratories (Hercules, CA).
Histopathology and immunohistochemistry
For histological analyses, bladders were fixed in methacarn (60% methanol, 30%
chloroform, and 10% glacial acetic acid) or formalin for 1-2 h at room temperature and
dehydrated in 70% ethanol overnight at 4ºC. They were then embedded in paraffin,
sectioned, and stained with hematoxylin and eosin (H/E) for light microscopy. For
immunofluorescence examination, unstained bladder sections were deparrafinized with
xylene (twice for 10 min), rinsed in 100% isopropanol (three times for 5 min), and
washed with running de-ionized water for 5 min. When indicated, antigen retrieval was
performed in Citrate Buffer (10mM NaCitrate pH 6.0) as previously described328,329.
Slides were washed in PBS for 5 min and in blocking buffer (5% Fetal Bovine Serum or
PBS with 1%BSA and 0.3% TritonX-100) for 1h at room temperature. This step was
followed by a PBS wash (three times for 5 min). The tissue sections were then blocked
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statically in blocking buffer for 30 min at room temperature. Primary antibodies, raised in
rabbit against Streptococcus Group D antigen (Lee Laboratories), against human nitric
oxide synthase 2 (NOS2 or iNOS; Santa Cruz Biotechnology), against rat NK-1 receptor
(Pierce Biotechnology, Rockford, IL), raised in goat against mouse uroplakin III (Santa
Cruz Biotechnology, Inc., CA) and against human substance P (Santa Cruz
Biotechnology), were added in blocking buffer at 1:500 dilution when indicated and
incubated at room temperature for 1 hour. After a PBS wash (three times for 5 min),
tissue sections were incubated with secondary antibody, Alexa Fluor 555-labeled donkey
anti-rabbit antibody and Alexa Fluor 488-labeled donkey anti-goat antibody, each diluted
1:1000 in blocking buffer for 30 min at room temperature. After PBS wash (once for 5
min), tissues were counterstained with TOPRO-3 (Molecular Probes) or Alexa Fluor 633conjugated WGA at 1:1000 dilution in PBS (second wash for 5 min) to reveal nuclear
morphology, when indicated. After a third PBS wash for 5 min, immunostained tissues
were mounted using Prolong Gold Antifade (Molecular Probes) and visualized by CLSM.
Flow cytometry
Single cell bladder suspensions were made from minced bladder tissues subjected to
collagenase/DNAse I digestion. Staining of surface markers was performed using FcR
block and fluorochrome-conjugated monoclonal antibodies (mAbs).
To immunophenotype the immune infiltrates, specific combinations of mAbs were
chosen which distinguish granulocytes (CD11b+Gr1+Ly6G+), monocytes (Ly6G-Ly6C+),
macrophages (CD11b+F4/80+), dendritic cells (CD11c+F4/80−), basophils (FccR1+),
eosinophils (SiglecF+), mast cells (cKit+), NK cells (NK1.1+), T cells
(CD3+CD4+/−CD8+/−), and B cells (CD19+). All antibodies were from BD Pharmagen,
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Ebioscience or Southern Biotech. Cells were counterstained with propidium iodide.
Activation status was determined using specific mAbs for MHC-II. Samples were
acquired on a FACScalibur (BD Biosciences) and data were analyzed using FlowJo
software (version 7.6.4). The absolute number of cellular infiltrates per bladder was
calculated by multiplying the percentage of each population from two parameter flow
cytometry data by the total number of isolated live cells, as determined by
hemocytometer count following Trypan blue staining.
Neutrophil depletion
Mice were rendered neutropenic as previously described 219. Briefly, an anti-Ly6G mAb
(1A8) from (Bio X Cell, West Lebanon, NH) was administered intraperitoneally on days
3 and 1 prior to implantation and bacterial challenge. Control mice received IgG isotype
control 2A3 (Bio X Cell) in the similar manner.
Gentamicin protection assay
To quantify intracellular and extracellular bacteria, bladders were aseptically harvested at
indicated time points. Bladders were cut in 4 parts and washed three times in 500 µl
PBS. The wash fractions were pooled, centrifuged at 500 rpm for 5 min to pellet
exfoliated bladder cells. The supernatants were then serially diluted and plated on LB
agar supplemented with appropriate antibiotics to obtain the extracellular bacterial
contents. The dissected bladders were treated with 100µg/ml gentamicin (Sigma-Aldrich)
for 90 min at 37oC. Following gentamicin treatment, the bladder tissue was washed twice
with PBS to eliminate residual antibiotics, homogenized in 1 ml PBS, serially diluted and
plated on LB agar with appropriate selection antibiotics for quantification of the
intracellular bacteria. CFU was enumerated after 24 h of growth at 37oC.
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UPEC reservoir reactivation
Non-implanted animals were infected with UTI89HK::GFP as described above. At
fourteen days post infection, urine was collected, serially diluted and plated for CFU and
a subset of animals implanted as described above. Animals determined to be bacteriuric
(bacterial loads greater than or equal to 104 CFU/ml in urine) as counted on titer plates
the next day were eliminated from further study. UPEC reservoir reactivation postimplantation was assessed by CFU enumeration of bacteria on implants and in the organs
3 or 5 days post-implantation (17 or 19 dpi). UTI89HK::GFP titers greater than 104
CFU/ml on implants or bladders were considered reactivation events.

Measures of

reactivation events of animals, which were non-bacteriuric at 14 dpi but non-implanted
served as controls.
Mannoside and antibiotic treatment
For pretreatment experiments, 50µl mannoside (ZH56; 5 mg/kg mouse body weight) or
PBS was administered intraperitoneally 30min prior to implantation as previously
described87. As indicated for pre-infection treatment, trimethoprim/sulfamethoxazole
(TMP-SMZ) was added at 54 and 270 µg/ml, respectively, to the drinking water for three
days prior to bacterial inoculation. The drinking water was changed every 24h.
To assess the effects of mannoside and/or TMP-SMZ on established infections, animals
were implanted and infected for 24h. At 24hpi, TMP-SMZ was added to the drinking at
the concentrations indicated above and ZH56 or PBS was administered i.p. 6h prior to
sacrifice. Animals were sacrificed 48hpi.
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IBC enumeration and visualization
Implanted and non-implanted animals were infected with UTI89 for 6h. When indicated,
ZH56 (5mg/kg) or PBS was administered i.p. at 30 min prior to implantation. At 6hpi,
bladders were harvested, bisected, splayed on silicone plates and fixed in 2%
paraformaldehyde. LacZ staining of whole bladders was performed as previously
described330. Punctate violet spots characteristic of IBCs were enumerated by light
microscopy.
For IBC visualization, animals were infected with UTI89 constitutively expressing GFP
(UTI89pCom-GFP). At the indicated time point, bladders were removed, bisected,
splayed, and fixed as described above. The splayed bladders were then incubated for 20
min at room temperature with Alexa Fluor 633-conjugated wheat germ agglutinin (WGA;
1:1000 in PBS; Molecular Probes) for staining of the bladder surface and, when
indicated, SYTO83 (1:1000 in PBS; Molecular Probes) to stain bacteria. Bladders were
rinsed with PBS, mounted using Prolong Gold antifade reagent (Invitrogen) and
examined with a Zeiss LSM510 confocal laser-scanning microscope under a 63X
objective. SYTO83 and WGA were excited at 543 and 633 nm, respectively.
Statistical methods
Comparisons between groups were conducted by nonparametric two tailed, MannWhitney U test using GraphPad Prism (GraphPad software). A p-value less than 0.05 was
considered significant. For in vivo experiments, values below the limit of detection
(LOD) were assigned the appropriate LOD value for statistical analyses. Colonization
and infection was defined as organs/implants with bacterial titers above the limit of
detection at 24 hpi.
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Table 3: List of strains used in this study
Species and Strains

Relevant
Antibiotic
resistance

E. faecalis
OG1RF WT

RifR, FusR

OG1RFΔatn

RifR, FusR

OG1RFΔsrtA

RifR, FusR

OG1RFΔsrtA/srtA

RifR, FusR, KanR

OG1RF ΔgelE

RifR, FusR

OG1RF Δeep

RifR, FusR

OG1RF Ωef0983

RifR, FusR, CmR

E. faecalis
OG1X

StrR

UTI89
UTI89ΔfimH
UTI89ΔsfaA-H

UTI89ΔsfaAH∆fimB-H

Characteristics
Parental enterococcal strain,
derived from the oral isolate from
OG1
OG1RF with an in-frame deletion
of atn, autolysin deficient
OG1RF with an in-frame deletion
of srtA, SrtA deficient
OG1RFΔsrtA ectopically
expressing a wild type copy of
srtA, SrtA positive
OG1RF with an in-frame deletion
of gelE, gelatinase deficient
OG1RF with an in-frame deletion
of eep, Eep defective
OG1RF with a transposon
insertion in ef0983, AhrC
defective
gelE negative from
nitrosoguanidine mutagenesis
Parental UPEC UTI89 strain,
cystitis isolate
UTI89 with an in-frame deletion
of fimH, type 1 pili defective
UTI89 with an in-frame deletion
of sfa operon, S pili defective

KanR CmR

UTI89ΔcsgA
UTI89ΔcsgB∆csgG
UTI89HK::GFP

KanR

UTI89pCOMGFP

KanR

UTI89 with in-frame deletion of
the sfa operon and the fim operon
from fimB to fimH, S and type1
pili defective
UTI89 with an in-frame deletion
of csgA, curli deficient
UTI89 with in-frame deletions of
csgB and csgG, curli deficient
UTI89 with an insertion of
kanamycin cassette and green
fluorescent protein (GFP) at the
HK site
UTI89 ectopically expressing GFP
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References
209

This study 210
This study 210
This study 210
103

This study,
Frank et al, in
preparation
This study 114
209, 331
282
75

This study,
Wright et al,
unpublished
This study
Wright et al,
unpublished
80

80

292

292

Table 4: List of plasmids used in this study
Name
pABG5

Relevant Antibiotic resistance
KanR, CmR (E. coli)
Kan500, Cm20 (E. faecalis)

pJRS233

Erm750 (E. coli)
Erm25 (E. faecalis)

pAL1

Kan50 (E. coli)
Kan500 (E. faecalis)

pAL1::SrtA

Kan50 (E. coli)
Kan500 (E. faecalis)
Kan50 (E. coli)

pCOM-GFP

Characteristics
Shuttle vector, containing
rofA promoter for
expression in Gram
Positive bacteria
Temperature sensitive
plasmid for generation of
in-frame deletions
Derivative of pABG5,
Cmr cassette, contains
rofA promoter
For complementation of
srtA deletion
For expression of GFP

References
332

311, 312

This study 210
This study 210
292

Table 5: List of primers used in this study
Primer
Sequence (5′-3′)
EF0799f1 GCTCTAGAAAGTTGCAGCTCCGGCAATGCCA
CAACCGACG
EF0799sewr GTTACCAAAGATAGCTATTTTTTTCAATCTTA
AATTAACCAACTTTCGTCCCCAACTTTCCTTT
TTTAACTTATATGT
EF0799sewf GTTACCAAAGATAGCTATTTTTTTCAATCTTA
AATTAACCAACTTTCGTCCCCAACTTTCCTTT
TTTAACTTATATGT
EF0799r1 GCTCTAGAACCCAGTTAACCGCAACTTCTGCT
TCATAAGC
EF0799f2 ATTTGCCACCTGCAGCCATT
EF0799r2 CCGCTCCCTCTTTCTACACG
EF3056e-f1 GGAATTCCCCCTCTACTAGCCTCCTTACCATT
TTAC
EF3056e-r1 GGAATTCCGTTGATAATGAGTCTGCCGCTAG
TGTATG
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Use
Amplification
of upstream
region of atn
Amplification
of upstream
region of atn
Amplification
of downstream
region of atn
Amplification
of downstream
region of atn
Screening
of atn deletion
Screening
of atn deletion
Screening
of srtA deletion
Screening
of srtA deletion

Reference
This study
210

This study
210

This study
210

This study
210

This study
210

This study
210

314
314

Table 6: Primers for confirmation of SNPs between OG1RF and OG1X
Primer
EF0243F1
EF0243R1
EF1218F1
EF1218R1
EF1349F1
EF1349R1
EF1778F1
EF1778R1
EF2575F1
EF2575R1
EF2587F1
EF2587R1
EF2983F1
EF2983R1
EF3157F1
EF3157F2
EF3157R1
EF3285F1
EF3285R1
EF3290F1
EF3290R1

Sequence (5′-3′)
GGT TGC TCT CTG TTT CTT CTT CTG
CGA CAC TAG AAA AGA TGC GCT TCC
GTG TTG AAA TAT ACG TTT TCC TTG CG
AAG TCA CCA CAA TCA AAC ATA ATG G
CG ACA GAT GTC ACT GCT TTA GC
GTC TCT CGG TTG TTG AAG TTC C
CAG AGA AAA TTC ATG CTC TTG AGC
TCG CTG TAA TTT TTT GGC GAT TGC
CAT GTG CGT TGA CTT CAT GCA ACG
GTG AAT AAG GTC CTA CAG CAG C
CTC AAT ACT AAC TCA AGT CAT AGC
GGT ACT GCC AAG GTA ATT TAA AGC
CAG GAT GAC CTC TAA AAA CCA TGC
CAC TAC GTA CAG CAT TTT TCC ACC
GCA AGC GGT GAT TCA AGC ATT CG
CTG ACA CAG CGA AAC AAT TGT TGC
CCA AGC TTG ATA ATG AAA TTT GGC
GTC GTA TTT ACA TCA GAA AGC G
ACC AAC TCG GGC ACC ATC G
AGA TAA GAT TGA AGA AGC AAC TGG
CAA ACT CTC TGG AAT TCA GTG C

Table 7: List of inhibitors and antibiotics used in this study
Name

Dosage/route

Dexamethasone
Sodium Phosphate

10mg/kg, i.p.30min
prior to implantation

CP-99,994
dihydrochloride

CP-96,345

Aminoguanidine
hydrochloride
Cyclophosphamide
Alfuzosin
hydrochloride

Mode of action
Glucocorticoid, antiinflammatory and
immunosuppressant

5-10mg/kg, i.p., i.v.,
s.c.30 min and 3h
post implantation
(when indicated)
5-10mg/kg, i.p., i.v.,
s.c, 30 min and 3h
post implantation
(when indicated)
200mg/kg 1h and 3h
post implantation
(when indicated)
150mg/kg at time of
infection
60µg/kg, 15min prior
to implantation

High affinity
neurokinin 1 receptor
(NK1R) antagonist
High affinity NK1R
antagonist
Irreversible inducible
nitric oxide synthase
(iNOS) inhibitor
Chemotherapeutic
agent/prodrug
α1 adrenoreceptor
antagonist
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Company/References
American Regent,
Inc., Shirley, NY

245

Tocris Bioscience,
Ellisville, MO

201,202

199

205

Tocris Bioscience

Tocris Bioscience
Tocris Bioscience

333,216

Tocris Bioscience

206,334
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